



Conference Program

145 Macquarie Street
SYDNEY NSW 2000
AUSTRALIA
Ph 61 2 9256 5454
Fax 61 2 9241 4586
Email gesa@gesa.org.au

Australian Gastroenterology Week 2007

24 - 27 October
Perth Convention Exhibition Centre



www.agw2007.com



AGW Venue

Perth Convention & Exhibition Centre
PERTH WESTERN AUSTRALIA

Telephone: + 61 (0) 8 9338 0300

Facsimile: + 61 (0) 8 9338 0309

Please note that the Perth Convention & Exhibition Centre is a non-smoking venue. Smoking is not permitted in any part of the venue including the exhibition halls and foyers.

Rooms

Exhibition

Exhibition Hall 1 (Pavilion1)

Sessions

Plenary

Riverside Theatre

Concurrent

Meeting Rooms 1/2/3

River View Rooms 4 & 5

Meeting Rooms 6 & 8

Media Centre

Media Suite

Speakers Support Centre

Meeting Room 12

AstraZeneca Hospitality

Exhibition Hall Office

Hosted By

- Gastroenterological Society of Australia

Participating Organisations

- Australasian Society for Parenteral and Enteral Nutrition (AuSPEN)
- Gastroenterological Nurses College of Australia (GENCA)

Contents

Welcome Messages	2
Organising Committee	3
Secretariat	4
International Speakers	4
Conference Information	5
Registration Entitlements	5
Identification	7
Nominated Accommodation Venues	7
General Information	8
Annual General Meetings	9
Sponsors & Exhibitors	9
Program	10
Exhibition Floor Plan	34
Poster Display	35
Invited Faculty	46
Sponsor Profiles	50
Future Dates	60

Welcome Messages



Paul Desmond

I would like to personally welcome you to AGW 2007. It is many years since AGW has been held in Perth and it is wonderful to have a new Convention Centre to allow us to travel back to this wonderful city. It is pleasing to see a record number of abstracts submitted for this meeting which allows the Society to showcase the breadth and depth of research in Gastroenterology in Australia.

It is very fitting that Noble Laureate Professor Barry Marshall will be presenting in his home town during our initial plenary session. I would also like to welcome our Bushell lecturer Professor Michael Kamm from St Mark's Hospital in London, an Australian expat, who has achieved international recognition for his work in inflammatory bowel disease and pelvic floor disorders.

We have a large number of other overseas speakers who I would personally like to welcome to Perth. I believe the Scientific Program Committee, chaired by Peter Katelaris, has assembled an outstanding program to provide our members with the latest information for our continuing education in conjunction with an extensive program of original research in all fields of gastroenterology in Australia.

I would also like to welcome members of the Australasian Society for Parenteral and Enteral Nutrition (AuSPEN) and our nursing colleagues. I am sure the meeting will be a wonderful learning and social experience.

Paul Desmond
President



Organising Committee



Peter Katelaris

On behalf of the Scientific Program Committee, welcome to Australian Gastroenterology Week for 2007. The meeting returns to Perth after an absence of 12 years. Among the many changes to the city is the new conference venue which provides us with excellent facilities for our meeting.

We are fortunate to have a distinguished international faculty. Professor Michael Kamm from St Mark's, London, is the Bushell lecturer and his lectures will focus on IBD and functional disorders of the colon. Professor Hugo Rosen (Denver) and Professor Bruce Bacon (St Louis) are the invitees of the ALA and will address issues in viral hepatitis and transplantation. Professor Michael Steer (Boston) will speak on mechanisms of pancreatitis while Professor John Baillie (Durham), the AGEA invitee, will contribute to the endoscopy program including the day long Clinical Update on Wednesday. Professor Robert Shulman (Houston) will contribute to the paediatric program on topics that include chronic pain and probiotics.

We are pleased that the Australasian Society for Parenteral and Enteral Nutrition (AuSPEN) is meeting with us again this year. International contributors in this area are Professor Alan Buchman (Chicago) and Professor Andre Van Gossum (Brussels).

The Endoscopy Clinical Update, October 24th is themed around emergencies in endoscopy and the concurrent Clinical Hepatology Update day will focus on viral hepatitis. The Thursday morning presidential plenary session will be a highlight of the meeting, featuring an address from the Society's only Nobel Laureate as well as from the Bushell lecturer and the recipients of the Distinguished Research Prize and Outstanding Clinician Award for 2007.

Throughout Thursday, Friday and Saturday, multiple concurrent sessions are scheduled so that at any one time there will usually be a choice of a luminal, liver, endoscopy or basic science subject with input from all the interest groups including IBD, GI Cancer and endoscopy. As well, an Endoscopy Learning Centre will operate throughout the meeting. The GENCA nurses have a full program overlapping and interacting with the core program. The dinner on Friday night will be preceded by a wine tasting hosted by Digby Cullen.

The program is the culmination of more than a year of planning and work by the Committee and I would like personally to thank all members of SPC (listed below) who have volunteered their time and ideas and worked hard to make the meeting happen. In particular I would like to thank Jon Watson, the local organiser and Elaine Siggins, our indomitable executive officer.

We trust you will enjoy not only the scientific content but also the collegiate and social aspects of the meeting.

Peter Katelaris
Chair, Scientific Program Committee

Scientific Program Committee

Chairman	Peter Katelaris
Meeting Organiser	Jon Watson
Asst. Meeting Organiser	Nicholas Kontorinis
Administration	Elaine Siggins
AGEA Representative	Ian Norton
ALA Representative	Grant Ramm
Paediatric Representative	Richard Couper
AuSPEN Representative	Andrew Davies
GENCA Representative	Lynn Rapley

Secretariat

Gastroenterological Society of Australia

145 Macquarie Street
SYDNEY NSW 2000
AUSTRALIA

Telephone: +61 2 9256 5454
Facsimile: +61 2 9241 4586
Email: gesa@gesa.org.au
Website: www.gesa.org.au
AGW website: www.agw2007.com

Invited International Speakers

Bushell Lecturer

Michael Kamm

Director Inflammatory Bowel Disease
& Physiology Units,
St Marks Hospital,
Harrow, England

Bruce Bacon

Head of Gastroenterology,
Saint Louis University,
Missouri, USA

John Baille

Head of Gastroenterology,
Wake Forest University
Health Sciences,
Durham, North Carolina, USA

Hugo Rosen

Waterman Professor of Medicine and
Immunology Division Head,
Gastroenterology & Hepatology
University of Colorado & Health
Sciences Centre,
Colorado, USA

Michael Steer

Professor of Surgery,
Tufts University School of Medicine,
Boston, Massachusetts, USA

Andre Van Gossum

Associate Professor,
Department of Gastroenterology &
Hepatopancreatology,
Erasme Hospital
Brussels, Belgium

Company Sponsored Speakers Baxter Healthcare

Alan Buchman

Associate Professor of Medicine,
Department of Gastroenterology
Northwestern University
Chicago, Illinois USA

Nutricia

Robert Shulman
Children's Nutrition Research Center
Baylor College of Medicine,
Houston, Texas, USA



Conference Information

Registration

The registration desk will be situated in the entry foyer to the Convention Centre and will be open at the following times:

Tuesday 23 October	16:00 – 18:00
Wednesday 24 October	07:00 – 16:00
Thursday 25 October	07:00 – 16:00
Friday 26 October	07:00 – 16:00
Saturday 27 October	08:00 – 14:00

Registration Entitlements

• 4 day registration (Wednesday – Saturday)

All conference sessions
 Morning, afternoon teas and lunches
 Conference documentation
 Name Badge (required to gain entry to sessions & exhibition hall)
 Satchel
 May purchase one (1) discounted conference dinner ticket @ \$70.

• 3 day registration (available for Thursday, Friday, Saturday only)

All conference sessions
 Morning, afternoon teas and lunches
 Conference documentation
 Name Badge (required to gain entry to sessions & exhibition hall)
 Satchel
 May purchase one (1) discounted conference dinner ticket @ \$70.

• 2 day Registration (available for Friday and Saturday only)

All conference sessions
 Morning, afternoon teas and lunches
 Conference documentation
 Name Badge (required to gain entry

to sessions & exhibition hall)
 Satchel

• One day attendance

All conference sessions
 Morning, afternoon tea and lunch (day of attendance)
 Conference documentation
 Name Badge (required to gain entry to sessions and exhibition hall)

• Exhibitors

Per booth purchased
 Two complimentary trade registrations which include:
 Company name badge
 Lunches, morning and afternoon teas; and
 Entry to conference sessions (room permitting)

• Per Exhibitor

One conference satchel and contents
 One electronic tracking system (two (2) systems with four booths or more).
 The right to purchase two discounted tickets to the conference dinner.

• Additional Registrations (Staff of Exhibiting Companies only)

Entry to the Exhibition Hall
 Lunches, morning and afternoon teas
 No entry to conference sessions.

Tickets

Delegates who have paid for “additional tickets” will find the appropriate tickets inside their registration envelope – please check that all tickets paid for are included when registering.

Catering

Morning, afternoon teas and lunches will be served in the Exhibition Pavilion. Special Diets that have been pre-booked can be found at the catering station with the sign “SPECIAL DIETS”.

Education Hub

The Education Hub is situated in the centre of the Exhibition Hall and houses the following;

- **Digestive Health Foundation-Supported by Gilead Sciences**
 Show casing a selection of resources developed by the DHF

- **Endoscopy Learning Centre Supported by Olympus Australia**
Featuring a selection of interesting & educational DVDs.
- **National Bowel Cancer Screening Program**
Information and material relating to the program.
- **Wiley - Blackwell**
Information on the Journal of Gastroenterology & Hepatology and other relevant publications.

Email

An email port is available in the exhibition area for delegates to check personal email messages. Considering the number of delegates expected, we ask that you are considerate of others by completing your email check as quickly as possible.

Electronic Devices

As a courtesy to speakers, delegates are requested to switch off mobile phones and pagers during sessions.

Entry

Entry to sessions and the Exhibition Hall 1 will be monitored. All participants will be issued with a name badge, which permits entry. Delegates not wearing the correct name badge may be refused entry.

Early Bird Case Discussions

Case discussions will be held on Thursday and Friday morning commencing at 07:15.

Wine Tasting "Best from the Margaret River"

The wine tasting will be incorporated into pre-dinner drinks on Friday evening. Digby Cullen will educate our taste buds by leading us through some of the best from the Region.

AGW Dinner

This event is proudly sponsored by an unrestricted education grant from all exhibitors of AGW 2007. The dinner will be held at the Convention Centre on Friday 26 October commencing at 19:15.

Speakers Support Centre

The support centre is in Meeting Room 12. This room will be open from 07:00 each day.

Speakers are requested to check in presentations at least three (3) hours prior to the presentation. All items checked in must be labelled with the room, session, and name of the speaker. Please ensure that items are picked up after the presentation. A technical operator will be in attendance to render assistance.

Please note that the organisers will endeavour to provide the highest level of service, however, failure to meet our guidelines may compromise the delivery of the service.

Session Chairs

As this meeting has a full program, Session Chairs are asked to meet their speakers in the appropriate session room at least 10 minutes prior to the

commencement of the session. It is also the chair's responsibility to ensure speakers do not exceed their allotted presentation and question time.

Exhibition

The Trade exhibition can be found in Exhibition Hall 1. This meeting has attracted a range of exhibitors covering pharmaceutical, medical instrument, medical publication and educational related organisations. We encourage you to visit the displays. Morning, afternoon teas and lunches will be served in this area.

Abstracts

All abstracts accepted for this meeting have been published in a supplementary edition of the Journal of Gastroenterology and Hepatology. Full registrants will receive a copy of the Abstract Book in their satchel. Extra copies of this book are not available.

Poster Display

The Display can be found in the exhibition foyer and pavilion. Posters will be on display throughout the meeting.

Presenters will be in attendance at the Posters on Thursday and Friday from 12:45 - 13:45.

The "Posters of Merit" session will be held in the exhibition area during lunch on Friday between 12:45 - 13:15.

Delegates are encouraged to visit the poster display and to attend the programmed session.













Identification

Please note that the streams and presentations are coded throughout the program.

Young Investigator Awards (YIA)

- YIA are awards made at Australian Gastroenterology week in recognition of the most meritorious research contributions by Young Investigators to the scientific program.
- The eight finalists for this year's awards will present on Thursday 25 October commencing at 11:10 in the Riverside Theatre.
- Each finalist will be presented with a certificate of achievement at the Award Presentations to be held on Friday 26 October commencing at 17:30 the overall winners will be announced at the AGW dinner on Friday evening.

Program Streams

	Free papers Plenary, GESA		GENCA		Paediatric		Early Bird Session
	AGEA		AUSPEN		Drug and Alcohol		
	ALA		IBD		DHF		

Nominated AGW Accommodation Venues

Best Western Emerald Hotel

24 Mount Street, Perth WA 6000

Ph: 08 9481 0866

Fax: 08 9321 4789

Medina Grand Perth

33 Mounts Bay Road, Perth WA 6000

PH: 08 9217 8000

FAX: 08 9217 8199

Pacific International Suites

305 Murray Street, Perth WA 6000

Ph: 08 9347 7000

Fax: 08 9347 7007

Duxton Hotel

1 St Georges Terrace, Perth WA 6000

PH: 08 9261 8000

FAX: 08 9261 8147

Mercure Hotel Perth

10 Irwin Street, Perth WA 6000

PH: 08 9326 7000

Fax: 08 9221 3344

Parmelia Hilton

14 Mill Street, Perth WA 6000

Ph: 08 9215 2000

Fax: 08 9215 2001

Holiday Inn City Centre

778 Hay Street, Perth WA 6000

Ph: 08 9261 7200

Fax: 08 9261 7255

Mounts Bay Waters Apartments

112 Mounts Bay Road, Perth WA 6000

Ph: 08 9213 5333

Fax: 08 9486 7998

Rydges Perth Hotel

815 Hay Street, Perth WA 6000

Ph: 08 9263 1800

Fax: 08 9263 1801

Ibis Hotel Perth

10 Irwin Street, Perth WA 6000

Ph: 08 9322 2844

Fax: 08 9481 6084

Novotel Langley

221 Adelaide Terrace, Perth WA 6000

Ph: 08 9221 1200

Fax: 08 9221 1669

General Information

Message Board

A message board will be situated in the registration area. Delegates are requested to check the board for messages as a personal service is not available.

Transport

Shuttle Buses "Ferring Ferries" will run between the nominated conference accommodation venues and the Convention Centre. A timetable will be available at each accommodation venue and in the registration area of the Convention Centre.

Shuttle will also run following the dinner on Friday evening.

Parking

Please note that the parking station at the Convention Centre is small and open to the public, therefore parking is limited, with the area often full early.

Business Centre

Various business services are available from the Information Desk at the centre. Services include photocopying, printing, faxing, internet connection, telephone and secretarial services. Charges apply and are payable in cash when these services are utilised.

Childcare

Please contact Dial an Angel [www:dialanangel.com](http://www.dialanangel.com)

Maintenance of Professional Standards (MOPS)

The Royal Australian College of Physicians (RACP) advises that participation in AGW will accrue the following points:

Attendance

- 0.5 points per hour

Presentation

- 3 credit points per presentation plus 0.5 credit points per hour for preparing the presentation.

The maximum claim for any one meeting is 20 credit points. The onus is on the individual Fellow to claim the points appropriate to their participation in the meeting.

GENCA Unit Visits

The bus for the Unit visits will depart from the front of the Convention Centre at **17:30 on Thursday 25 October**. Tickets must have been pre-booked for this event.

Travel Grants

Corporate Sponsors of GESA and Major Sponsors to AGW have made it possible for the Organising Committee to provide Travel Grants to support clinicians, scientists and nurses in the early stages of their career to gain education and experience in the field of Gastroenterology and Hepatology, especially in areas of research relevant to the field, through attendance at Australian Gastroenterology Week.



Annual General Meetings

Wednesday 24 October

- 12:00 Australian Liver Association (ALA)
- 17:00 Australian Gastrointestinal Endoscopy Association (AGEA)

Thursday 25 October

- 16:00 Australasian Society for Parenteral and Enteral Nutrition (AuSPEN)

Friday 26 October

- 16:45 Gastroenterological Nurses College of Australia
- 17:30 Gastroenterological Society of Australia

Sponsors & Exhibitors

Members of the Organising Committee and all participating organisations gratefully acknowledge the support of the following companies towards this meeting:

Corporate Sponsors

AstraZeneca
Nycomed
Janssen-Cilag

AGW Sponsors

Abbott Australasia
Bristol Myers Squibb
Gilead Sciences
National Bowel Cancer Screening Program
Olympus Australia
Orphan Australia
Pharmatel Fresenius Kabi
Roche Products
Schering-Plough

Other Sponsorship

- **Corporate Sponsors**
Satchels
Lanyards
- **Ferring Pharmaceuticals**
Shuttle Buses
- **Gilead Sciences**
Digestive Health Foundation Booth
- **Olympus Australia**
Endoscopy Learning Centre

- **Roche Products**
Pads
- **National Bowel Cancer Screening Program**
Pens
- **International Speakers**
Baxter Healthcare
Nutricia



PROGRAM

Wednesday 24 October 2007

Australian Gastrointestinal Endoscopy Association
 Clinical Update
 Endoscopic Emergencies











MEETING ROOMS 1/2/3		
08:30 – 10:00	SESSION 1	
	Video Forum	Chairs: J Baillie/ M Bourke
10:00 – 10:30	MORNING TEA	

10:30 – 1200	SESSION 2	
	Blockage of the GI Tract	Chairs: M Schoeman/ R Leong
10:30 – 10:50	Caustic Injury of the Oesophagus	P Craig
10:50 – 11:10	Oesophageal Foreign Bodies: Where, tricks and techniques	W Selby
11:10 – 11:30	Complications of Bariatric surgery – role of the endoscopist	P Prichard
11:30 – 11:50	Colonic Obstruction and Pseudo-Obstruction	A Chong
11:50 – 12:00	Discussion	
12:00 – 12:30	State of the Art Lecture: Is ERCP headed for extinction?	J Ballie
12:30 – 13:30	LUNCH	

13:30 – 15:00	SESSION 3	
	Bleeding – Case Study	Chairs: D Ormonde/ A Chong
13:30 – 13:45	Emergency Endoscopy – Where and When	P Edwards
13:45 – 14:00	Management of UGI Bleeding in 2007	C Bell
14:00 – 14:15	Non-Upper GI Bleeding	G Brown
14:15 – 14:30	Imaging for Obscure Overt Bleeding (CT, Angio, Nuclear)	J Ferguson
14:30 – 14:45	Approach to Massive Transfusion	N Staples
14:45 – 15:00	Discussion	
15:00 – 15:30	AFTENOON TEA	

15:30 – 17:00	SESSION 4	
	When it all Goes Wrong	Chairs: C Bell/ TBC
15:30 – 15:50	An Early Approach to Complications	M Bourke
15:50 – 16:10	ERCP Complications	I Norton
16:10 – 16:30	Why and When the System Fails	D Mackender
16:30 – 16:50	Indemnity Issues for Gastroenterologists	P Johnston

Colour codes

	Free papers Plenary, GESA		GENCA		Paediatric		Early Bird Session
	AGEA		AUSPEN		Drug and Alcohol		
	ALA		IBD		DHF		

16:50 – 17:00	Discussion	
17:00 – 17:30	AGEA Annual General Meeting	Chair: I Norton

Australian Liver Association

Clinical Update

Emerging and Difficult Issues in Viral Hepatitis

RIVER VIEW ROOM 4		
09:50 – 12:30	SESSION 1	
	Controversies in Chronic Hepatitis B	Chair: D Crawford
09:50 – 10:00	Introduction and Welcome	D Crawford
10:00 – 10:30	Antiviral drug resistant mutants – Why do they develop and strategies to overcome resistance	S Locarnini
10:30 – 11:00	Patient selection for Chronic Hepatitis B Virus – Has the answer been revealed?	A Thompson
11:00 – 11:30	HBV/HIV co-infection: Current strategies on management	S Lewin
11:30 – 12:00	Current issues in liver transplantation for Chronic Hepatitis B Virus infection	H Rosen
12:00 – 12:30	ALA Annual General Meeting	
12:30 – 13:30	LUNCH	

13:30 – 15:30	SESSION 2	
	Difficulties in HCV	Chair: W Cheng
13:30 – 14:00	Hepatitis C in the human liver transplant model	H Rosen
14:00 – 14:20	Acute HCV: When to treat and with what?	G Dore
14:20 – 14:40	HCV, Fat and Iron – Implications for disease progression	B Bacon
14:40 – 15:00	HCV and renal injury: Cause and effects	M Levy
15:00 – 15:10	Discussion	
15:10 – 15:30	AFTERNOON TEA	

15:30 – 17:00	SESSION 3	
	Emerging issues in Viral Hepatitis	Chair: M Levy
15:30 – 15:50	Therapies for HCV: Insights into the future	A Zekry
15:50 – 16:10	The role of Early Virological Testing for HCV: Predicting therapeutic response	S Pianko

PROGRAM (continued)

16:10 – 16:20	Discussion	
16:20 – 17:00	Debate: The PBAC has sufficient evidence to licence Combination Therapy for Chronic HBV	For: G McCaughan Against: P Desmond

GENCA – IBD

MEETING ROOM 8		
11:00 – 12:30	SESSION 1	
		Chairs: S Buckton/ S Mason
10:30 – 11:00	Pathophysiology of IBD – Basics to advanced	M Haines
11:00 – 11:30	Medical strategies in managing IBD	M Howlett
11:30 – 12:00	Surgical strategies in IBD	G Makin
12:00 – 12:30	Managing fatigue	J Iser
12:30 – 13:30	LUNCH	

13:30 – 15:00	SESSION 2	
		Chairs: B Headon/D Kukic
13:30 – 14:00	Stress, anxiety and depression in IBD	A Mikocka-Walus
14:00 – 14:30	Telephone assessment – running a patient helpline	S Buckton, S Mason
14:30 – 15:00	Monitoring immunomodulatory therapy	M Sparrow
15:00 – 15:30	AFTERNOON TEA	

15:30 – 17:30	SESSION 3	
		Chairs: P Leach/A McFarlane
15:30 – 16:00	Sharing Best Practice/Local Projects	P Leach, L Reid
16:00 – 16:30	Transitional care for teenagers and young adults	S Buckton
16:30 – 17:30	GENCA IBD Special Interest Group Meeting	

RIVER VIEW ROOM 4		
18:00 – 19:30	Symposium: New Directions in Gastroenterology – Supported by Nycomed	Chair: J Watson
18:00 – 18:45	Gut ecology: Therapeutic manipulation of the gut milieu in inflammatory bowel diseases	M Kamm
18:45 – 19:30	The management of HCV in 2007	H Rosen

Thursday 25 October – Core Program

CONCURRENT 1		MEETING ROOMS 1/2/3
07:15 – 08:15	Early Bird Session Sorting out abnormal iron studies	J Olynyk

CONCURRENT 2		RIVER VIEW ROOM 4
07:15 – 08:15	Early Bird Session Colorectal Cancer screening: the pros and cons of different techniques	G Forbes

CONCURRENT 3		RIVER VIEW ROOM 5
07:30 – 08:15	Early Bird Session GENCA Introduction to AGW for first timers	GENCA B.O.M

PLENARY		RIVERSIDE THEATRE
08:30 – 10:00	RIVERSIDE THEATRE	
08:30 – 08:40	Opening and Welcome Presentation of the Distinguished Service Award	Chairs: P Desmond/ P Katelaris
08:40 – 09:10	Bushell Lecture Creative management of large bowel functional disorders	M Kamm
09:10 – 09:40	Nobel Laureate: Helicobacter Connections	B Marshall
09:40 – 10:10	Distinguished Research Prize Recipient	P Bhathal
10:10 – 10:30	MORNING TEA	

10:30 – 12:30	Concurrent Sessions x 4	
CONCURRENT 1		RIVERSIDE THEATRE
	Presentation of the Outstanding Mentor Award	Chairs: D Crawford/ J Watson
10:30 – 11:00	Outstanding Clinician Recipient On the Value of the Clinical Project	P Kerlin
11:00 – 12:30	Plenary Free Papers – Young Investigator Finalists	
11:00 – 11:12	Prediction of Crohn's disease aggression through the analysis of NOD2/CARD15 sequence variations	M Bhullar
11:12 – 11:24	Pancreatic stellate cells stimulate pancreatic cancer growth and metastasis: findings of a novel orthotopic model of pancreatic cancer	A Vonlaufen
11:24 – 11:36	Dietary fodmaps increase delivery of water and fermentable substrates to the proximal colon	J Barrett

PROGRAM (continued)

11:36 – 11:48	Alcohol consumption further modulates hepcidin gene expression in an animal model of Haemochromatosis	M Heritage
11:48 – 12:00	Intrahepatic and serum markers of HBV replication and their relationship to serum HBeAg titres: Implications for the use of quantitative HBeAg testing as a predictive tool for treatment outcome	A Thompson
12:00 – 12:12	Angiotensin 1-7 infusion reduces hepatic fibrosis in the bile duct ligated rat	J Lubel
12:12 – 12:24	Reduction in HCV related liver disease associated with BG Virus C in HCV/HIV co-infection	M Berzsenyi
12:24 – 12:36	Role of bone-marrow derived stem cells in liver injury	M Eckersley-Maslin

CONCURRENT 2		MEETING ROOM 6
	GENCA Liver	Chair: A Blunn
10:30 – 11:00	Hepatitis Viruses: New Clarity in Alphabet Soup	G Farrell
11:00 – 11:15	Scratching the Itch: Managing Pruritis	S Strasser
11:15 – 11:25	A New Course in Hep C Nursing Education	S Mason
11:25 – 11:55	What Makes a Good Liver Nurse? - Crossing the Boundaries: Professional v Personal	R Batey/ V Fragomelli

CONCURRENT 3		MEETING ROOM 8
	AuSPEN: Intestinal Failure Symposium	Chair: A Davies
10:30 – 10:55	The development of an Australian Intestinal Failure Program	J Bines
10:55 – 11:20	Intestinal failure: When to refer for intestinal transplantation	A Buchman
11:20 – 11:30	The nutritional management of intestinal failure: A Dietician's role	E Rogers
11:30 – 11:40	The nutritional management of intestinal failure: A Pharmacist's role	A Poon
11:40 – 11:50	The nutritional management of intestinal failure: A Nurse's role	H Shalley
11:50 – 12:00	AuSPEN/GESA supporting the management of intestinal failure	K McIlroy
12:00 – 12:30	Panel discussion	

CONCURRENT 4		RIVER VIEW ROOM 5
	GENCA: TB – Clinical Updates	Chair: J Pang
10:30 – 11:00	Managing Patients with TB	J Waring
11:00 – 11:20	Air conditioning and Immunisation – what we should know!	R McCann
11:20 – 11:40	CXR screening, room standards & other interesting "bits"	M Scully

11:40 – 12:00	Complications of Bronchoscopy and Specimen Collection	S Morey
12:30 – 14:00	LUNCH	

14:00 – 15:30	Concurrent Sessions x 6	
CONCURRENT 1	RIVERSIDE THEATRE	
	ALA: Accelerated Liver Disease – Two Hits and Transplantation Symposium	Chair: G. Ramm
14:00 – 14:30	State of the Art Lecture:	H Rosen
	Recurrent HCV after liver transplantation: the natural history and patient selection for antiviral therapy	
14:30 – 15:00	Iron and alcohol: More pieces to fit into the jigsaw	L Fletcher
15:00 – 15:30	Steatosis as a co-factor for other liver diseases	G Macdonald

CONCURRENT 2	MEETING ROOM 1/2/3	
	DHF: Health Impacts of the Australian Water Crisis Symposium	Chair: S Strasser
14:00 – 14:30	The Water Crisis in Australia – the Problem and Possible Solutions	J Antenucci
14:30 – 15:00	Fate of Enteric Organisms in the Environment	M Hipsey
15:00 – 15:30	Water Quality and Gastroenteritis – Is recycled Water a Risk?	K Leder

CONCURRENT 3	MEETING ROOM 6	
	Free Papers: Small Bowel and Colon	Chair: P Gibson/ M Grimm
14:00 – 14:10	MLH1-93G>A is associated with hereditary and sporadic microsatellite unstable Colorectal Cancer	V Whitehall
14:10 – 14:20	Use of a high-resolution miniature endoscope in the investigation of murine models of intestinal inflammation?	I Lawrance
14:20 – 14:30	Lyprinol™ partially ameliorates 5-Flourouracil-induced mucositis in the rat	G Howarth
14:30 – 14:40	Quality, clinical impact and tolerance of CT Enteroclysis in patients with suspected small bowel disease	A Moss
14:40 – 14:50	The 13c sucrose breath test: A non-invasive technique to assess SI mucosal integrity in the critically ill	C Burgstad
14:50 – 15:00	Iron replacement in Inflammatory Bowel Disease – Improved outcomes	M De Silva
15:00 – 15:10	Relative incidence of Mycobacterium Avium Subsp. Paratuberculosis in a population-based cohort of Crohn's disease patients	R Geary

PROGRAM (continued)

15:10 – 15:20	Thiopurine metabolite testing – Clinical utility in an Australian cohort of IBD patients with inadequately controlled disease	M Haines
15:20 – 15:30	Mucosal changes following massive small bowel resection: Current dogma debunked	P Pereira-Fantini

CONCURRENT 4	MEETING ROOM 8	
	AuSPEN: Short Bowel Syndrome Symposium	Chair: J Bines
14:00 – 14:20	Intestinal adaptation: the key to improved clinical outcome	P Periera-Fantini
14:20 – 14:40	Changes in GI motility following MSBR	B Southwell
14:40 – 15:00	Microbial flora, bacterial growth and SBS	T Florin
15:00 – 15:30	Short Bowel Syndrome: A case and discussion	A Van Gossum

CONCURRENT 5	RIVER VIEW ROOM 4	
	AGEA: Recurrent Pancreatitis – A Case Study	Chairs: I Norton/ M Bourke
14:00 – 14:20	Workup if an Initial Attack of Pancreatitis	D Routley
14:20 – 14:40	Definitions and Mechanisms of Pancreatitis	M Steer
14:40 – 15:00	Endoscopic Management of Pancreatic Fluid Collection	D Devonshire
15:00 – 15:20	Recurrent Pancreatitis	J Baillie
15:20 – 15:30	Discussion	

CONCURRENT 6	RIVER VIEW ROOM 5	
	GENCA: Motivational Speaker:	Chair: R Brown
14:00 – 15:30	Bastards and Bitches – How to Deal With Them and Avoid Becoming One!	A Horobin
15:30 – 16:00	AFTERNOON TEA	

16:00 – 17:30	Concurrent Sessions x 6	
CONCURRENT 1	RIVERSIDE THEATRE	
	Free Papers: Viral Hepatitis	Chairs: D Dowling/ TBC
16:00 – 16:10	Treatment responses in Asians infected with Hepatitis C Genotype 1 virus	K Yan
16:10 – 16:20	Hepatitis C is associated with more neuropsychiatric symptoms than other liver diseases, and more neuropsychiatric and gastrointestinal symptoms than in community controls: A case-control study	C Lang

16:20 – 16:30	Sustained virologic response with Albinterferon Alfa-2B plus Ribavirin treatment in IFN-naïve, chronic Hepatitis C Genotype 1 patients	S Pianko
16:30 – 16:40	Effect of Adiponectin on the cellular immune response in Chronic HCV infection	C Palmer
16:40 – 16:50	HCV associated Cryoglobulinaemia – Clinical presentation and treatment response	J Dobson
16:50 – 17:00	Hepascore accurately predicts fibrosis and reflects treatment response in chronic Hepatitis B infection	L Adams
17:00 – 17:10	Hepatitis B Virus (HBV) screening and Lamivudine prophylaxis in patients commencing systemic chemotherapy for haematological malignancy	G Stott
17:10 – 17:20	A randomised study to assess the safety and efficacy of Adefovir Dipivoxil substitution for HBIG in liver transplantation patients receiving long-term low dose IM HBIG and Lamivudine prophylaxis	S Patterson
17:20 – 17:30	A prospective study on the safety and efficacy of Lamivudine and Adefovir Dipivoxil prophylaxis in HBsAg positive liver transplantation candidates	S Patterson

CONCURRENT 2	MEETING ROOMS 1/2/3	
	GI Cancer Symposium	Chairs: G Young/F Macrae
16:00 – 16:30	Update on the National Bowel Cancer Screening Program	M Otuszewski
16:30 – 17:00	New Developments in Screening Technologies for Colorectal Cancer	G Young
17:00 – 17:30	The CSIRO Colonoscopy Simulator	S Ourselin

CONCURRENT 3	MEETING ROOM 6	
	Free Papers: Clinical Practice	Chairs: L Hillman/ R Knight
16:00 – 16:10	The management of Helicobacter Pylori infection in patients with a history of Penicillin allergy	A Kwok
16:10 – 16:20	Cameron's erosions often have a high transfusion requirement which is corrected by surgery	C Jayasekera
16:20 – 16:30	Surgery for early Oesophageal Adenocarcinoma? Analysis of lymphatic spread and prognostic factors	A Barbour
16:30 – 16:40	The role of faecal Lactoferrin in the evaluation of hospitalised patients with diarrhoea	D van Langenberg
16:40 – 16:50	Clinicopathological features of pancreatic solid Pseudopapillary Tumours	R Leong

PROGRAM (continued)

16:50 – 17:00	The balloon expulsion test predicts response to biofeedback therapy in Irritable Bowel Syndrome and Functional Constipation	V Suttor
17:00 – 17:10	Satisfaction of IBS patients with medical consultations: role of patient's expectations	V Knott
17:10 – 17:20	Familial Colorectal Cancer: Patients, their first-degree relatives and Colorectal Cancer screening	L Gellart
17:20 – 17:30	A retrospective study of the impact of changes in colonoscopy process on polyp detection	R Skoien

CONCURRENT 4	MEETING ROOM 8	
16:00 – 17:15	AuSPEN Annual General Meeting	Chair: A Davies
17:15 – 18:00	AuSPEN Intestinal Failure Special Interest Group	

CONCURRENT 5	RIVER VIEW ROOM 4	
	AGEA: Preparation for Endoscopy	Chairs: P Prichard/ A Chong
16:00 – 16:20	Anticoagulation and Endoscopy	D Ormonde
16:20 – 16:40	Cardiac Stents and Anticoagulants	M Hands
16:40 – 17:00	Update on Antibiotic Prophylaxis	M Schoeman
17:00 – 17:20	Modification of Endoscopy for High Risk Patients	M Bourke
17:20 – 17:30	Discussion	

CONCURRENT 6	RIVER VIEW ROOM 5	
	GENCA Novice Presenters and Free Papers	Chair: L Rapley

	RIVER VIEW ROOM 5	
	Therapeutic Endoscopy and Hepatology in the USA, 2007 Symposium. Supported by AstraZeneca	Chair: P Katelaris
18:00 – 18:45	Therapeutic endoscopy: have we gone too far?	J Baillie
18:45 – 19:30	Hepatitis C: Diagnosis and Treatment	B Bacon

Friday 26 October

CONCURRENT 1	MEETING ROOMS 1/2/3	
07:15 – 08:15	Early Bird Session IBD Australia Database	T Florin

	RIVER VIEW ROOM 4	
07:15 – 08:15	Early Bird Session Difficult Cases in HBV infection	A Nicoll

	RIVER VIEW ROOM 5	
07:15 – 08:15	Early Bird Session Surviving as a VMO: A guide for Trainees and Fellows (and Consultants!)	R Knight

08:30 – 10:00	Concurrent Sessions x 6	
CONCURRENT 1	RIVERSIDE THEATRE	
	IBS and Functional Gastrointestinal Disorders Symposium	Chairs: P Gibson/ G Holtmann
08:30 – 08:50	Traditional Pathophysiologic concepts: Time for a reappraisal?	J Andrews
08:50 – 09:10	Inflammation and Immune response in functional GI disorders	G Holtmann
09:10 – 09:30	Treatment issues: Established and alternative treatments	S Haag
09:30 – 09:50	Is there a place for nutrition as a cause or therapy?	S Shepherd
09:50 – 10:00	Discussion	

CONCURRENT 2	MEETING ROOMS 1/2/3	
	IBD Australia Symposium	Chair: T Florin
08:30 – 09:00	Mild ileitis in the patients with IBS - is it Crohn's and what to do?	TBC
09:00 – 09:30	Optimising Thiopurine Treatment	M Sparrow
09:30 – 10:00	Management of severe ulcerative colitis	M Kamm

CONCURRENT 3	MEETING ROOM 6	
	Free Papers: Basic Science – Hepatology 1	Chairs: J Olynyk/G Ramm
08:30 – 08:40	CD147 regulation of Hepatocyte derived matrix Metalloproteases: A novel pathway involved in liver fibrosis	S Richardson
08:40 – 08:50	Kupffer Cell-derived CTGF and TGFβ mediate the profibrogenic effects of Leptin In vitro	J Wang

PROGRAM (continued)

08:50 – 09:00	Ferroportin: Membrane topology and functional characterisation of disease-causing mutations	N Subramaniam
09:00 – 09:10	Iron uptake by Transferrin Receptor 2 in human hepatoma cells	D Trinder
09:10 – 09:20	Light and Lymphotoxin- β acting via Lymphotoxin- β receptor are able to modulate the expression of key profibrogenic mediators in the hepatic stellate cell	R Ruddell
09:20 – 09:30	Roles of Fibroblast Activation Protein (FAP) and Dipeptidyl Peptidase IV (DPIV) identified in an experimental model of Liver Fibrosis	G McCaughan
09:30 – 09:40	Deletion of the Thrombin Receptor Gene, PAR1, ameliorates liver fibrosis and decreases TGF β expression by hepatic stellate cells in a murine model of Cirrhosis	V Knight
09:40 – 09:50	Early metabolic changes parallel liver injury in high fat-fed foz/foz mice	C Larter
09:50 – 10:00	Hepatoprotective strategies against Ischaemia Reperfusion injury in Murine Liver Steatosis and Steatohepatitis	N Teoh

CONCURRENT 4	MEETING ROOM 8	
	Free Papers: Endoscopy 1	Chairs: G Brown/ M Barclay
08:30 – 08:40	Colonoscopic polypectomy of large polyps: Safety and long term outcomes	M Salama
08:40 – 08:50	Colonoscopy withdrawal times and polyp detection rates: a New Zealand perspective	G Lim
08:50 – 09:00	A population-based study of missed and new cancers after gastroscopy	S Raftopoulos
09:00 – 09:10	National survey of colonoscopy quality training in Australia in 2007	E Lee
09:10 – 09:20	Need for transfusion in patients with small intestinal Angioectasias seen at capsule endoscopy – Evaluating the significance of “red spots”	T Heap
09:20 – 09:30	Efficacy of therapeutic Double-Balloon Enteroscopy in obscure gastrointestinal bleeding	V Suttor
09:30 – 09:40	The performance of Double-balloon Enteroscopy in the assessment and treatment of capsule endoscopy findings	S Prasad
09:40 – 09:50	The impact of CT Enteroscopy in addition to Double-balloon Enteroscopy in the investigation of gastrointestinal bleeding	V Suttor
09:50 – 10:00	Endoscopic removal of Oesophageal self expanding metal stents – Is it feasible and safe?	M Swan

CONCURRENT 5		RIVER VIEW ROOM 4
	GENCA: Professional Issues	Chair: R Harvey
08:30 – 08:50	Mentoring – Making this work for you	L Hamlin
08:50 – 09:10	Find 'em & Keep 'em: How to Hold Up Your Staff when you Can't Hold Up yourself!	D Thacker
09:10 – 09:30	Producing Competent Practitioners Through Staff Education and Orientation	D Jones
09:30 – 09:50	Credentialing – What Is It & Why Do We Have It In Our Speciality	R Harvey
09:50 – 10:00	Discussion	

CONCURRENT 6		RIVER VIEW ROOM 5
	AuSPEN: Nutrition and Gastroenterology	Chair: P Woods
08:30 – 08:55	Nutritional management in patients with Inflammatory Bowel Disease	A Van Gossum
08:55 – 09:20	Nutritional Management in patients with Cystic Fibrosis	S King
09:20 – 09:45	Nutritional management in patients with liver disease	D Crawford
09:45 – 10:00	Panel discussion	
10:00 – 10:30	MORNING TEA	

10:30 – 12:00	Concurrent Sessions x 5	
CONCURRENT 1		RIVERSIDE THEATRE
	Addiction medicine loves your liver! Drug and Alcohol Symposium	Chair: R Batey
10:30 – 11:00	Alcohol – not your average toxin	S Worrall
11:00 – 11:30	HCV treatment in D & A and GP land	R Hallinan
11:30 – 12:00	Livers on ICE	P Haber

CONCURRENT 2		MEETING ROOM 1/2/3
	IBD Australia: Upper GI Enteritidis : Coeliac Symposium	Chair: T Florin
10:30 – 11:00	Wheat and what else?	G Tanner
11:00 – 11:30	Emerging alternatives to diet	R Anderson
11:30 – 12:30	IBD Australia Annual General Meeting	

PROGRAM (continued)

CONCURRENT 3	MEETING ROOM 6	
	Free Papers: Motility	Chair: G Hebbard/ R Holloway
10:30 – 10:40	Abnormalities in nerves and pacemaker cells in children with functional constipation	B Southwell
10:40 – 10:50	Digestive tract responses to feeding and to distension in spinal cord injury	V Suttor
10:50 – 11:00	Severe constipation demonstrates aberrant spatio-temporal linkage among sequential colonic propagating sequences	P Dinning
11:00 – 11:10	Disturbed distal colonic transit contributes to persistent anorectal symptoms and dysfunction in patients following External Beam Radiation Therapy (RT) for Prostate Carcinoma (CaP)	F Bartholomeusz
11:10 – 11:20	Frequency of colonic complexes in health and severe constipation: Defining a new hallmark of colonic dysmotility	P Dinning
11:20 – 11:30	Acid sensitisation of Oesophageal mucosal afferents: Implications for symptom perception in patients with Gastro-Oesophageal Reflux Diseases (GORD) and functional heartburn	M Szczesniak
11:30 – 11:40	Differences in visceral sensory function in complicated and uncomplicated peptic ulcer disease	M Gururatsakul
11:40 – 11:50	Multiple roles of Acetylcholine in the intestine-location of Muscarinic receptors	A Harrington
11:50 – 12:00	Long term outcome following pneumatic dilatation for Idiopathic Achalasia	T Elliott

CONCURRENT 4	MEETING ROOM 8	
	Free Papers: Hepatology - Other	Chair: J Olynyk
10:30 – 10:40	Non-citrus fruit intake modifies iron status in an Australian population	E Milward
10:40 – 10:50	HFE-associated hereditary Haemochromatosis disease in a prospective study of 31,192 individuals	K Allen
10:50 – 11:00	Genomic alterations in a DNA repair-deficient mouse model of accelerated liver carcinogenesis (Teoh)	N Teoh
11:00 – 11:10	BK Virus: A new cause of chronic renal dysfunction following liver transplantation (OLT)	M Salama
11:10 – 11:20	Measures of insulin resistance vary with serum ALT concentrations in apparently healthy subjects without known NAFLD	M Ryan
11:20 – 11:30	Spontaneous Bacterial Peritonitis (SBP) prophylaxis: Trimethoprim-Sulfamethoxazole V Norfloxacin	S Lontos

11:30 – 11:40	Urotensin II increases portal pressure and induces hepatic fibrosis	W Kemp
11:40 – 11:50	Terlipressin therapy for renal dysfunction and Hypnoatraemia in patients with liver failure	E Prakoso
11:50 – 12:00	Rapamycin is and anti-fibrotic agent	C Popa

CONCURRENT 5		RIVER VIEW ROOM 4
	GENCA: Professional Issues (cont.)	Chair: L Swain
10:30 – 11:00	Portfolio Development – Is It Necessary and How Should It Be Done?	L Hamlin
11:00 – 11:20	Professional Indemnity – Should Nurses Have It?	J Parnell
11:20 – 11:40	Horizontal violence – Does It Really Exist and Why Does It Occur?	L Rapley
11:40 – 12:00	Lessons on Governance – It's Definitely NOT a Board Game!	D Roche

CONCURRENT 6		RIVER VIEW ROOM 5
	AuSPEN: Specialised Nutrition Support: What's the latest?	Chair: A Spencer
10:30 – 10:50	TPN-associated hepatobiliary disease	A Buchman
10:50 – 11:15	Nutrition support in the ICU – results of a 2007 international survey	A Davies
11:15 – 11:35	Acute Pancreatitis – The nutritional management plan in 2007	P Woods
11:35 – 11:45	Cost effectiveness of nutrition support in the prevention of pressure ulcers Australian hospitals	M Banks
11:45 – 11:55	Analysis of in patient parenteral nutrition provision at two Auckland centres, 2005-2007	R Walmsley

12:00 – 12:30	State of the Art Lectures x 3	
	RIVERSIDE THEATRE	
	SOA Lecture 1	Chair M Apte
	Cell biological events which lead to acute pancreatitis	M Steer

		MEETING ROOMS 1/2/3
	SOA Lecture 2	Chair: P Katelaris
	Biological therapies in IBD - when and how to use them	M Kamm

PROGRAM (continued)

RIVER VIEW ROOM 5		
	SOA Lecture 3	Chair: I Nyulasi
	Ethical aspects of PEG placement for artificial nutrition	A Van Gossum
12:30 – 14:00	LUNCH	

EXHIBITION HALL		
13:30 – 14:00	Posters of Merit	J Olynyk/P Kerlin

13:00 – 15:30	Concurrent Sessions x 6	
CONCURRENT 1		
RIVERSIDE THEATRE		
13:00 – 13:45	DAA Nutrition support	Special Interest Group
14:00 – 15:30	AuSPEN/DHF: Nutrition in the Gastroenterological Community Symposium	Chair: P Gibson
14:00 – 14:20	Nutritional issues after Bariatric surgery	N Zarshenas
14:20 – 14:40	Coeliac Disease – Current nutritional management	S Shepherd
14:40 – 15:00	Allergies and intolerance: What's the difference?	L Hodge
15:00 – 15:30	Common Allergies/Intolerances and their management – A case and discussion	S Shepherd Panel: K Allen, P Gibson, R Heine, L Hodge

CONCURRENT 2		
MEETING ROOMS 1/2/3		
	GENCA: Research – What's It all About?	Chair: D Jones
14:00 – 14:30	Narrowing the Research-Practice Gap: A Professional Mandate for Gastro Nurses	R Michael
14:30 – 14:45	Writing for Publication	L Hamlin
14:45 – 15:00	How To Work Through a Literature Review	R Michael
15:00 – 15:20	What is The Joanna Briggs Institute – How Does It Help?	J Robertson
15:20 – 15:30	Discussion	

CONCURRENT 3		
MEETING ROOM 6		
	AHA Annual General Meeting and Symposium	Chairs: N Kontorinis/ W Cheng
13:30	Annual General Meeting	
14:00 – 14:05	Welcome and introduction	L Totten

14:05 – 14:25	Estimated prevalence of HCV related cirrhosis and HCC	M Law
14:25 – 14:50	Management of decompensating cirrhotics	TBC
14:50 – 15:10	Current management of patients undergoing liver transplantation	L Adams
15:10 – 15:30	Management of HCC	J Olynyk

CONCURRENT 4	MEETING ROOM 8	
	Free Papers: IBD - Science	Chair: G Radford-Smith/ R Geary
14:00 – 14:10	Proteomic analysis of differential protein expression in Inflammatory Bowel Disease	R Leong
14:10 – 14:20	Reduced Alpha-defensin expression is not associated with NOD2 mutation status in Ileal Crohn's disease	L Simms
14:20 – 14:30	The ATG16L1 variant (THR300ALA) is confirmed as a susceptibility locus in Crohn's disease and may also be associated with Ulcerative Colitis in Australian IBD patients	L Simms
14:30 – 14:40	The GLI1 gene as a risk factor for Ulcerative Colitis	M Barclay
14:40 – 14:50	A new IBD susceptibility gene is identified in a large Australian case-control study	G Radford-Smith
14:50 – 15:00	Differential gene expression between Crohn's disease and non-inflammatory bowel disease controls in a paediatric population	H Sim
15:00 – 15:10	Pathophysiological effects of Muramyl Dipeptide in a novel coculture model of epithelial monocyte interaction	P Tyrer
15:10 – 15:20	Immunophenotyping of Inflammatory Bowel Disease (IBD) using a cluster of differentiation (CD) antibody micorarray	G Pavendranathan
15:20 – 15:30	HLA, TPMT and ITPA genotypes and susceptibility to Azothioprine hypersensitivity reactions (HSR) in Inflammatory Bowel Disease (IBD) patients	R Geary

CONCURRENT 5	RIVER VIEW ROOM 4	
	AGEA: Mucosal Imaging	Chairs: S Cho/ P Craig
14:0 – 14:20	Oesophagus: NBI/Zoom.Acteic Acid/Chromoendoscopy	W Tam
14:20 – 14:40	Colon: NBI/Trendy Endoscopes/Chromoendoscopy	M Appleyard
14:40 – 15:00	Optical Biopsy Techniques	R Leong
15:00 – 15:20	EUS: What it Can Do and What it Can't Do	D Williams
15:20 – 15:30	Discussion	

PROGRAM (continued)

CONCURRENT 6	RIVER VIEW ROOM 5	
	Paediatric Transitional Care Symposium	Chair: P Lewindon
14:00 – 14:20	Issues in Emotional Psychological and Lifestyle Transition	D Payne
14:20 – 14:35	Transition for Paediatric GI Patients	D Cameron
14:35 – 14:50	Adult Viewpoint	W Connell
14:50 – 15:05	Hypnotherapy for Irritable Bowel Syndrome	A Webb
15:05 – 15:20	Eosinophilic Oesophagitis – Thoughts on Pathogenesis	D Forbes
15:20 – 15:30	Discussion	
15:30 – 16:00	AFTERNOON TEA	

16:00 – 17:30	Concurrent Sessions x 5	
CONCURRENT 1	RIVERSIDE THEATRE	
	Free Papers: IBD - Clinical	Chair: I Lawrance/ W Connell
16:00 – 16:10	The effect of reduction of poorly absorbed, highly fermentable short-chain carbohydrates (FODMAPs) on the symptoms of patients with Inflammatory Bowel Disease	R Geary
16:10 – 16:20	Inconsistencies and inadequacies in the use and monitoring of immunomodulatory drugs in patients with Inflammatory Bowel Disease	L Reid
16:20 – 16:30	5 year outcome of newly-diagnosed outpatients with Crohn's Disease from one institution	J Wilson
16:30 – 16:40	The use of Infliximab in the prevention of colectomy in severe and refractory Ulcerative Colitis	R Willert
16:40 – 16:50	The clinical utility of 6-Mercaptopurine in patients with Inflammatory Bowel disease after Azothioprine therapy related pancreatitis	C Hair
16:50 – 17:00	Surgery for perianal disease in a population-based Crohn's Disease cohort	R Geary
17:00- 17:30	GESA Awards Ceremony	Chair: J Olynyk
17:30 – 18:00	GESA Annual General Meeting	Chair: P Desmond

CONCURRENT 2	MEETING ROOM 6	
	AHA Workshop: Issues and challenges managing patients with advanced liver disease	Chairs: M Fenech/ A Blunn
16:00 – 16:05	Welcome and introduction	L Totten
16:05 – 17:30	Interactive session: Management of patients pre and post transplant	Panel TBC

CONCURRENT 3	MEETING ROOMS 1/2/3	
	GENCA Awards Ceremony and Annual General Meeting	Chair: A McKnight
16:00 – 16:45	Awards and Grants Ceremony	
16:45 – 17:30	Annual General Meeting and Open Forum	

CONCURRENT 4	RIVER VIEW ROOM 4	
	AGEA: Endoscopy Training in the 21st Century	Chair: D Ormonde
16:00 – 16:20	The Role of Simulation and Skills Based Courses in Endoscopy Training	B Laurence
16:20 – 16:40	The Role of Training in the Endoscopy Room	I Norton
16:40 – 17:00	The Aims of training: What are They?	TBC
17:00 – 17:20	The NETI – Towards a National Endoscopy Curriculum	G Brown
17:20 – 17:30	Discussion	

CONCURRENT 5	RIVER VIEW ROOM 5	
	AuSPEN: Malnutrition in the Hospitalised Patient Symposium	Chair: G Hardy
16:00 – 16:25	The skeleton in the closet: Where are we with malnutrition in 2007?	M Banks
16:25 – 16:50	Malnutrition in elderly Australians: the reality	S Daniells
16:50 – 17:30	Debate: All hospitalised patients need a nutrition assessment on arrival	A Buchman, P Gibson

19:15	BALLROOM	
	Wine Tasting & Dinner	

PROGRAM (continued)

Saturday 27 October

07:15 – 08:15	RIVER VIEW ROOM 4	
	AuSPEN Research Special Interest Group Meeting	Chair: A Davies

08:30 – 10:00	Concurrent Sessions x 5	
CONCURRENT 1	RIVERSIDE THEATRE	
	ALA: Clinico-Pathological Correlations in Liver Disease – Patients with a liver mass Symposium	Chair: D Crawford
08:30 – 09:00	Case Study 1: Benign liver masses in the non-cirrhotic liver	
	Case presentation	R Ryan
	Discussion and Overview	L Adams
09:00 – 09:30	Case Study 2: Malignant tumours in the non-cirrhotic liver	
	Case presentation	R Ryan
	Discussion and Overview	G Jeffrey
09:30 – 10:00	Case Study 3: Malignant tumours in the cirrhotic liver	
	Case presentation	R Ryan
	Discussion and Overview	M McCullen

CONCURRENT 2	MEETING ROOMS 1/2/3	
08:30 – 10:00	AGEA/SAC Training: Discussion of Syllabus and Training Requirements in Gastroenterology and Endoscopy	Chairs: I Norton/S Bell

CONCURRENT 3	MEETING ROOM 6	
	Free Papers: GI Cancer	Chair: B Leggett/ F Macrae
08:30 – 08:40	Triptolide decreases pancreatic cancer growth in vitro and in vivo by inhibition of heat shock protein 70 (HSP70)	P Phillips
08:40 – 08:50	Mucins in Helicobacter Pylori infection- A dynamic and responsive defence	S Linden
08:50 – 09:00	The contribution of bone marrow derived cells to solid organ malignancy	D Worthley
09:00 – 09:10	Prognostic factors in Oesophageal Cancer – The importance of Lymph Nodes	S Thompson
09:10 – 09:20	Is it important to encourage patients to undergo initial and repeated Faecal Occult Blood Testing for Colorectal Cancer?	M Veysey
09:20 – 09:30	Secreted protein acidic and rich in Cysteine (SPARC): A prognostic marker in Colorectal Cancer?	I Lawrance

09:30 – 09:40	Relationship between genotoxin-induced DNA damage and homeostatic responses in rats colonic epithelium	L Nyskohus
09:40 – 09:50	Transarterial chemoembolization of Hepatocellular Carcinoma is well tolerated in patients with compensated cirrhosis: Results of a prospective study	V Knight
09:50 – 10:00	Leptin and the Risk of Barrett's Oesophagus	B Kendall

CONCURRENT 4		RIVER VIEW ROOM 4
	AuSPEN: Home Nutrition Support Symposium	Chair D Russell
08:30 – 08:55	Home PN in a single centre over 20 years – Lessons learnt	A Van Gossum
08:55 – 09:15	The AusPEN home PN registry – Lessons learnt in our region	L Gillanders
09:15 – 09:35	Home PN – Preventing complications	A Buchman
09:35 – 09:55	Home EN – What is the future?	I Nyulasi
09:55 – 10:00	Discussion	

CONCURRENT 5		RIVER VIEW ROOM 5
	GENCA Symposium	Chair: J Stonestreet
08:30 – 08:40	What's New With Capsules?	E Eyres
08:40 – 08:50	Newest Treatment Options for Barrett's Oesophagus	I Norton
08:50 – 09:00	What is EMR?	D Ormonde
09:00 – 09:10	How Does Endoscopic Ultrasound Work?	S Edmunds
09:10 – 09:20	When To Use Double-Balloon Enteroscopy	C Siah
09:30 – 09:40	What's Happening with CT Colangiography?	TBC
09:40 – 09:50	What Is the Purpose of Anal Manometry?	G Hool
09:50 – 10:00	Discussion	
10:00 – 10:30	MORNING TEA	

10:30 – 12:00	Concurrent Sessions x 5	
CONCURRENT 1		RIVERSIDE THEATRE
	Gastro Oesophageal Reflux Disease Symposium	Chairs: P Katelaris/ G Holtmann
10:30 – 10:50	Defining GORD and the underlying disease mechanism	G Holtmann
10:50 – 11:10	Extraintestinal Symptoms	P Katelaris
11:10 – 11:30	Treatment: The past, the present and the future	R Holloway

PROGRAM (continued)

11:30 – 11:50	Beyond acid: Treatment from the basic scientists view	A Blackshaw
11:50 – 12:00	Discussion	

CONCURRENT 2	MEETING ROOMS 1/2/3	
10:30 – 12:00	Free Papers: Paediatric and Nutrition	Chairs: R Couper, A Day
10:30 – 10:40	Delayed gastric emptying in diabetic children and non-diabetic siblings	S Kritas
10:40 – 10:50	Quality of life is low in children with slow transit constipation (STC)	M Clarke
10:50 – 11:00	Hypnotherapy is highly effective in paediatric IBS: Exciting uses for an old phenomenon	A Webb
11:00 – 11:10	An assessment of novel Anti-gliadin in assays in screening children with GI symptoms for Coeliac disease	A Day
11:10 – 11:20	Serum 25-Hydroxy-vitamin D deficiency in children with IBD treated with enteral nutrition vs steroids	A Day
11:20 – 11:30	Selenium is protective against Colon Cancer in Azoxymethane-treated mice: Influence on molecular targets	Y Hu
11:30 – 11:40	Serum prealbumin correlates with both nutritional status and nutritional risk in critically ill patients	S Ferrie
11:40 – 11:50	Suppression of Azoxymethane-induced Colon Cancer development in rats by dietary resistant starch	R Le Leu
11:50 – 12:00	Medium-chain fatty acid modulation of cell viability in the CACO-2 and IEC-6 cell lines	J Fauser

CONCURRENT 3	MEETING ROOM 6	
10:30 – 12:00	Free Papers: Endoscopy 2	Chairs: M Schoeman/ TBC
10:30 – 10:40	Improving patients attendance rates in endoscopy	B Draper
10:40 – 10:50	Confocal Endomicroscopy in the evaluation of Coeliac Disease – A prospective validation study	R Leong
10:50 – 11:00	Endoscopic Ultrasound in patients with a dilated bile duct, normal liver function tests and negative cross-sectional imaging	D Segarasingam
11:00 – 11:10	Experience of Endoscopic Ultrasound for pancreatic cystic lesions in a tertiary teaching hospital	S Prasad
11:10 – 11:20	The safety and technical success of Endoscopic Ampullectomy – A single centre Australian experience	A Mishra
11:20 – 11:30	Small intestinal tumours: Not so uncommon. Double-Balloon Enteroscopy is an essential diagnostic and therapeutic modality	C Siah

11:30 – 11:40	Capsule Enteroscopy prior to Double-Balloon Enteroscopy in obscure gastrointestinal bleeding: Selecting the best diagnostic modality	V Suttor
11:40 – 11:50	A canine model for training in endoscopic submucosal dissection	G Forbes
11:50 – 12:00	Endoscopic management of chronic radiation Proctitis – an audit of 6 year experience at a single centre	M Swan

CONCURRENT 4		RIVER VIEW ROOM 4
	AuSPEN: Feeding Intolerance: Barriers to Successful Feeding	Chair: A Davies
10:30 – 10:50	Absorption and malabsorption: Understanding the pathophysiology	J Bines
10:50 – 11:15	Continuous versus intermittent feeding	R Shulman
11:15- 11:35	Sugar intolerance: Approach to diagnosis and management	J Barrett
11:35 – 11:45	The effect of probiotics on breath hydrogen patterns after lactulose, small intestinal permeability and symptoms in IBS patients with an early breath hydrogen rise – A proof of concept study	J Barrett
11:45 – 11:55	Is protein supplementation more beneficial than Colostrum in the treatment of short bowel syndrome?	S Thomas

CONCURRENT 5		RIVER VIEW ROOM 5
	GENCA: What Happens After The Endoscopy?	Chair: W Blomberg
10:30 – 10:50	Surgical sites and procedures	R Hodder
10:50 – 11:10	Management of post-op pain	L Hellier
11:10 – 11:30	Management of post-op wound infection - dressings	J Wright
11:30 – 11:50	Home management – Teaching families to care for a PEG	C McCrae
11:50 – 12:15	Chemotherapy – The Role and Timing	C Cameron
12:15 – 12:30	Discussion	

12:00 – 12:30	State of the Art Lectures x 2	
	MEETING ROOM 1/2/3	
	SOA Lecture 1	Chair: D Forbes
	Chronic Abdominal Pain	R Shulman

PROGRAM (continued)

	RIVER VIEW ROOM 4	
	SOA Lecture 2	Chair: A Thomson
	Somewhere over the rainbow: Better therapies for IBD on the horizon	A Buchman
12:30 – 14:00	LUNCH	

14:00 – 15:30	Concurrent Sessions x 4	
CONCURRENT 1	RIVERSIDE THEATRE	
	Free Papers: Basic Science Hepatology 2 and General	Chair: M Levy/ L Adams
14:00 - 14:10	Development of an in vitro model to assess the interaction of HIV and Hepatitis B Virus (HBV) in human Hepatocytes	D Iser
14:10 – 14:20	NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: An eleven year follow-up study	O Waters
14:20 – 14:30	Visceral adiposity measured by MRI predicts disease severity in NASH, whereas DEXA fails	D van der Poorten
14:30 – 14:40	Serum Alanine Aminotransferase levels decrease further with carbohydrate than fat restriction in insulin resistant adults	M Ryan
14:40 – 14:50	Factors affecting severity of Fatty Liver Disease in patients undergoing laparoscopic gastric banding surgery for obesity	H Berry
14:50 – 15:00	Suppression of LPS and IL-6 signalling by iron deficiency alters expression of the liver-derived iron regulatory peptide hepcidin	G Anderson
15:00 – 15:10	Characterising the clinical spectrum of hepatic iron load using MRI Ferriscan in suspected HFE and non HFE iron overloaded patients	T Tan
15:10 – 15:20	Prevalence of elevated IGG4 as a marker of Autoimmune Sclerosing Cholangitis in patients labelled as Primary Sclerosing Cholangitis	R Ryan
15:20 – 15:30	Hepatitis B Virus in migrant antenatal mothers: High seroprevalence but poor long term care	M Guirgis

CONCURRENT 2	MEETING ROOMS 1/2/3	
	AGEA: Capsule Endoscopy	Chair: M Appleyard
14:00 – 14:15	Capsule Endoscopy for Small Bowel Disease: An Update	A Taylor
14:15 – 14:30	Balloon Enteroscopy – When and How? One Balloon or Two?	G Brown
14:30 – 14:45	Cases to Highlight Role of Enteroscopy in Abnormal Capsule Studies	M Appleyard
14:45 – 15:00	Capsule Endoscopy – New Technology and Indications	F Macrae
15:00 – 15:15	Capsule Endoscopy in Australia	W Selby
15:15 – 15:30	Discussion	

CONCURRENT 3	MEETING ROOM 6	
	Paediatric: Eating Disorders Symposium	Chair: R Couper
14:00 – 14:20	Probiotics	R Shulman
14:20 – 14:35	Delayed Hypersensitivity	R Heine
14:35 – 14:50	Peanut Allergy	K Allen
14:50 – 15:05	Enteral Feeding and Paediatric IBD	A Day
15:05 – 15:20	Rotavirus Vaccination National Rollout	J Bines
15:20 – 15:30	Discussion	

CONCURRENT 4	RIVER VIEW ROOM 4	
13:00 – 13:45	PN Pharmacist's AuSPEN: Nutrition Support Guidelines	Chair: K McIlroy Special Interest Group
14:00 – 14:25	The 2006 ESPEN Guidelines for EN – Gastroenterology highlights	A Van Gossum
14:25 – 14:45	So many guidelines on nutrition in ICU – Which should we use?	A Davies
14:45 – 15:05	Do we need Australasian or International nutrition guidelines?	I Nyulasi
15:05 – 15:15	Discussion	All presenters
15:15 – 15:30	Presentation of awards and close of conference	K McIlroy

Exhibition Floor Plan

Exhibitors Booth Number

3 M Australia	34
Abbott Australasia	28
Aspen Pharmacare Pty Ltd	25
AstraZeneca	30
Baxter Healthcare	13
Boston Scientific	29
Bristol Myers Squibb Australia	32
Colocap Pharmaceuticals	3
Conmed Linvatec	38
Cook Australia	14
C.R. Kennedy	44
CSL Bioplasma	4
CTEC	2
Device Technologies	24a
Digestive Health Foundation	21
Endomed	1
Endoscopy Learning Centre	21
Endotherapeutics	36
Endovations	35
Endosoft	24b
Experien Medical Finance	5
Ferring Pharmaceuticals	22
Flolite Industries	6
Fujinon Australia	27
Gallay Medical & Scientific	7
Genzyme Australasia	12
Gilead Sciences	18
Given Imaging	26
Hydralyte	23
In Vitro Technologies	10
Janssen-Cilag	15
Matrix Surgical	9
National Bowel Cancer Screening Program	21
Neomedix Systems	8
Novartis Medical Nutrition	37
Nutricia Australia	43
Nycomed	19
Olympus Australia	20
Orphan Australia	16
Pharmatel Fresenius Kabi	31
PSK Connectors	40
Roche Products	33
Rymed	11
Schering-Plough	17
Smartline Machinery	39
Virtual Medical Centre	42
Whiteley Medical Centre	41
Wiley - Blackwell	21



Related Organisations

Australian Crohn's & Colitis Association	Counter
Australasian Society for HIV Medicine	Counter
Coeliac Society of Australia	Counter
Gastroenterological Nurses College of Australia	Counter

Poster Display

The poster display is located in the Foyer and the Exhibition Hall and is grouped into the following categories.

Luminal: Basic Science

Luminal: Clinical

Liver:

Posters will be on display for the entire meeting. We encourage delegates to view the posters on display and to take part in the discussion sessions on Thursday and Friday from 12:45 – 13:45.

LUMINAL: Basic Science

- 1 Red Blood Cell Methotrexate Polyglutamate Concentrations in Inflammatory Bowel Disease
Barclay M, Brooks A, Begg E, Zhang M, Frampton C.
- 2 Anti-Platelet Therapy with Clopidogrel or Dipyridamole has no Significant Effect on DSS-Induced Murine Colitis
Lust M, Moore G, Brown S, Bell S, Connell W, Elliott P, Slavin J, Nandurkar H, Cowan P, Desmond P, d'Apice A.
- 3 Over-expression of Glutathione Peroxidase with Two Isoforms of Superoxide Dismutases has no Significant Effect on Experimental Colitis in Mice
Lust M, Mysore T, Moore G, Brown S, Bell S, Connell W, Elliott P, Slavin J, Cowan P, Desmond P, d'Apice A.
- 4 Differential Induction of Apoptosis by Butyrate in Kato III and Caco-2 Cells is Related to the Rate of Butyrate Metabolism and P53 Status
Matthews G, Howarth G, Butler R.
- 5 A Simple Method for the Determination of Large Bowel Mucosal 5-ASA Levels Using High Performance Liquid Chromatography
Haines M, Geary R, Rose R, Gibson P.
- 6 WNT Blockade During Postnatal Growth of the Small Intestine Preferentially Reduces Crypt Hyperplasia and not Crypt Fission
Fausser J, Howarth G, Butler R, Cummins A.
- 7 Inhibition Of Dipeptidyl Peptidase Activity Increases Circulating Glucagon-Like Peptide-2 During Experimental Colitis In Mice
Yazbeck R, Howarth G, Demuth H, Holst J, Abbott C.
- 8 Dextran Sulphate Sodium Induced Colitis Modifies Small Intestinal Villus Height and Crypt Depth Potentially Regulated by Dipeptidyl Peptidase Activity
Yazbeck R, Abbott C, Mashtoub S, Wendland A, Jennings R, Leach M, Demuth H, Butler R, Howarth G.
- 9 *Lactobacillus Fermentum* BR11 and Fructo-Oligosaccharide Partially Reduce Jejunal Inflammation but not Overall Damage Severity of 5-Fluorouracil-Induced Mucositis in Rats
Smith C, Buter R, Howarth G.
- 10 High Red Meat Diets Induce Greater Numbers of Colonic DNA Double-Strand Breaks than White Meat: Attenuation by High Amylose Maize Starch
Conlon M, Toden S, Bird A, Topping D.

- 11 IL23R is an IBD Susceptibility Gene: Confirmation in an Australian Cohort.
Fowler E, Simms L, Doecke J, Zhao Z, Cooley R, Webb P, Hayward N, Whiteman D, Florin T, Montgomery G, Cavanaugh J, Radford-Smith G.
- 12 A Novel NOD2 Haplotype Interacts with TLR4 A299G in Association with Colonic Crohn's Disease, and Global Meta Analysis Confirms TLR4 A299G as a Crohn's Disease Susceptibility Gene
Hume G, Fowler E, Doecke J, Simms L, Huang N, Florin T, Radford-Smith G.
- 13 The Impact of GNB3 Genotype on Symptom Response During a Standardised Nutrient Challenge Test
Gururatsakul M, Adam B, Liebrechts T, Bredack C, Downie-Doyle S, Lester S, Holloway R, Talley N, Siffert W, Holtmann G.
- 14 Baseline Cytokinesis Blocked Micronucleus (CBMN) Index Correlates with Gastrointestinal Sequelae Including Anal Sphincter Morphology 1 Year After Radiation Therapy (RT) for Carcinoma of the Prostate (CAP)
Yeoh E, Di Matteo A, Botten R, Butters J, Salisbury C, Dhillon V, Olver I, Holloway R, Fenech M.
- 15 Encapsulated Omega-3 Fatty Acids Regulate Azoxymethane (AOM)-Induced DNA Damage in the Rat.
Nyskohus L, Hu Y, Le Leu R, Young G.

LUMINAL: Clinical

- 16 Psychological Disorders and Quality of Life in South Australian Outpatients with Inflammatory Bowel Disease, Irritable Bowel Syndrome and Chronic Hepatitis C: A Cross-Sectional Investigation
Mikocka-Walus A, Turnbull D, Moulding N, Wilson I, Andrews J, Holtmann G.
- 17 The Management of Patients with Haematemesis and Melaena Admitted Under a Gastroenterology Unit
Efthymiou M, Badov D.
- 18 Acute Food Bolus Impaction and Eosinophilic Oesophagitis
Efthymiou M, Roberts S.
- 19 Clinical Practice Amongst Paediatric Gastroenterologists for Childhood IBS
Webb A, Catto-Smith A, Kukuruzovic R, Sawyer S.
- 20 Reasons for Non-Compliance with Five-Yearly Screening Flexible Sigmoidoscopy
Viiala C, Olynyk J.
- 21 Pattern of Medication use in a Population-Based Inflammatory Bowel Disease Cohort in New Zealand
Barclay M, Ailibouni R, Shirley P, Geary R.
- 22 Routine Duodenal Biopsy Increases the Yield of Diagnosing Coeliac Disease in Patients Undergoing Upper Gastrointestinal Endoscopy
Simring A, Eslick G, Kalantar J.
- 23 Audit of Blood Test Monitoring for Patients on Azathioprine or 6-MP for Inflammatory Bowel Disease
Hoar J, Brown R, Geary R, Barclay M.
- 24 Improvements in Percutaneous Endoscopic Gastrostomy (PEG) Tube Management with Establishment Of The IPOS Team
Barrett J, McCrae C.
- 25 Development of a Parenteral Nutrition Specific Order Form to Minimise Clinical Risk Associated with Delivery.
Kiss N, Hall A, Loh E, Kirsas S, Comodo D.

- 26 Oral Peppermint Oil does not Reduce Pain Associated with Screening Flexible Sigmoidoscopy
Viiala C, Olynyk J.
- 27 Body Image and Sexuality in Inflammatory Bowel Disease; the Patients' Perspective
Muller K, Prosser R, Andrews J.
- 28 Interspecialty Communication Predicts the Quality of Care for Patients with Upper Gastrointestinal Bleeding
Hewett D, Watson B, Gallois C, Ward M, Leggett B.
- 29 Delays to Discharge can be Reduced with Improved Ward Procedures
Draper B, Tan M, Chow E, Sandford J, Boseley K, Bampton P, Young G.
- 30 IBS And Outpatient Services: Towards the Development of an Empirical Model of Health Care Utilisation
Knott, V, Andrews J.
- 31 Colorectal Cancer Screening Practices: a Comparison of General Practice and Specialist Approach
Gellert L, Schnitzler M, Bell C.
- 32 Intravenous Saline Pre-Hydration Significantly Reduces Hypotension in Patients Undergoing Outpatient Colonoscopy: A Randomised, Controlled Trial
Bromley J, Dodd J, Shadbolt B, Taupin D.
- 33 Infliximab Rescue Therapy for Hospitalised Patients with Severe, Steroid Refractory Ulcerative Colitis
Wiseman E, Leong R, Connor S.
- 34 A Prospective Study of Purine Antagonist Therapy in Patients with Crohn's Disease
Vigh S, Cooley R, Radford Smith G.
- 35 Poor Response to Infliximab in Patients with Steroid- Refractory or Steroid--Dependent Ulcerative Colitis
Wiseman E, Leong R, Connor S.
- 36 **WITHDRAWN**
- 37 Changes in Body Mass Index (BMI) in Patients with Crohn's Disease (CD) Between Onset of Symptoms and Diagnosis
Chapman-Kiddell C, Templeton D, Radford-Smith G.
- 38 Use of 5-Aminosalicylate Preparations in Ulcerative Colitis: Preliminary Analyses of Disease Outcomes
Cooley R, Gray S, Radford-Smith G.
- 39 Irritable Bowel Syndrome (IBS), Psychological Co-Morbidity and Rome III Criteria in Australian Referral Hospital Outpatient Setting
Mikocka-Walus A, Turnbull D, Moulding N, Wilson I, Andrews J, Holtmann G.
- 40 Treatment of Ulcerative Colitis with Dehydroepiandrosterone – A Case Report
Stephens S, Morrison N.
- 41 CT Enterography using Intraluminal Air as a Negative Contrast Material
Utano K, Endo K, Togashi K, Sugimoto H.
- 42 Preoperative T Staging of Colorectal Cancer using CT Colonography
Utano K, Togashi K, Endo K, Sasaki J, Miyakura Y, Horie H, Sugimoto H.
- 43 Resectional Surgery Characteristics in a Population-Based Inflammatory Bowel Disease (IBD) Cohort
Chang Y-H, Geary R, Reilly M, Barclay M, Frizelle F.

- 
- 44 **WITHDRAWN**
- 45 The use of Mycophenolate Mofetil and Tacrolimus in the Treatment of Resistant IBD
Tan T, Philpott J, Lawrance I.
- 46 Progression of Ulcerative Colitis to Collagenous Colitis: Chance, Evolution or Association?
Haque M, Florin T.
- 47 Early Colonoscopy is Associated with a Shorter Length of Stay in Acute Lower Gastrointestinal Bleeding
Shim L, Eslick G, Grehan M.
- 48 Cerebral Venous Thrombosis Associated with Ulcerative Colitis
De Cruz P, Lust M, Trost N, Gerraty R, Wall A, Connell W.
- 49 Methotrexate Treatment of Refractory Sprue
Chung A, Teo E, Alexander B, Cummins A.
- 50 The Marsh Grading System Underestimates Disease Severity in Coeliac Disease
Chung A, Alexander B, Teo E, Thompson F, Cummins A.
- 51 T-Staging of Rectal Cancer using Evaluation of Circumferential Extent by CT Colonography
Kimura Y, Togashi K, Endo K, Utano K, Koinuma K, Miyakura Y, Horie H, Sugimoto H, Yasuda Y.
- 52 Natural History of Perianal Crohn's Disease
Burger D, Radford-Smith G.
- 53 Colostrum Supplementation Restores IGF-1 Levels and Alters Muscle Morphology Following Massive Small Bowel Resection (MSBR)
Pereira-Fantini P, Thomas S, Fuller P, Bines J.
- 54 Bone Mineral Density in Coeliac Subjects before and after a Gluten-Free Diet
Chung A, Alexander B, Teo E, Cummins A.
- 55 Ascertainment Methods for Inflammatory Bowel Disease Case Capture in a Hospital Patient Population
what is the best Option?
Gray K, Cooley R, Radford-Smith G.
- 56 Audit of Capsule Endoscopy (CE) in Royal Perth Hospital
Kelly M, Siah C, Zimmerman M.
- 57 Crohn's Disease in the Arabic Population of South Western Sydney
Natfaji A, Tydd T, Alrubaie A, Samuel D, Meredith C, Batey R, Leong R.
- 58 Elevated Bilirubin in Acute Appendicitis
Macdonald T, Wills V.
- 59 Constipation as a Predictor of Colorectal Cancer at Colonoscopy
Kwok A, Shing G, Katelaris P, Jones D.
- 60 Prevalence of Serrated Polyp: is there a Difference between Australia and Japan?
Togashi K, Hewett D, Spring K, Kurashina K, Horie H, Yasuda Y, Appleyard M, Jass J, Leggett B.
- 61 An Australian Experience of Gastric and Duodenal Screening in Familial Adenomatous Polyposis (FAP)
Walker T, Tang K, Skinner I, Chen R.

- 62 EUS In Acute Upper Gastrointestinal Tract Bleeding. A Case Report
Argyrides J, Tam W.
- 63 ERCP With Per-Oral Choledochoscopy ("Baby" Scope) for the Diagnosis of Biliary Strictures of Uncertain Aetiology: A Preliminary Report of Two Cases
Pavendranathan G, Kaffes A.
- 64 Capsule Endoscopy in Orofacial Granulomatosis
Ibrahim M, Macrae F, Cameron D, Brown G, Aldred M, Stella D, Wiesenfeld D, Talacko A.
- 65 Adequacy of Non-Propofol Sedation for Endoscopy
Hazeldine S, Fritschi L, Griffin J, Forbes G.
- 66 Endoscopic Submucosal Dissection (ESD) of a High-Grade Dysplastic Lesion in the Gastric Cardia
A Case Report
Tam W.
- 67 Utilisation of Capsule Endoscopy in Variceal Screening and Surveillance
Smith B, Jeffrey G, Adams L, Leber J, Blanchard J, Garas G.
- 68 A Prospective Study to Evaluate the Aetiologies and Associated Risk Factors of Upper Gastrointestinal (UGI) Bleeding
Sandhu D, Chen R.
- 69 Outcome of Large Polyps Identified at Colonoscopy
Smith B, Forbes G.
- 70 Adjuvant Argon Plasma Coagulation In Piecemeal Polypectomy Of Advanced Laterally Spreading Sessile Colorectal Polyps
Swan M, Sievert W, Devonshire D.
- 71 How Common is Tissue Transglutaminase Positivity in Australia
Chin M, Mallon D, Cullen D, Olynyk J, Pearce C.
- 72 Patient Comfort in Colonoscopy can be Improved in the Absence of Anaesthetists!
Draper B, Sandford J, Hollington P, Lillie P, Bampton P.
- 73 Most Lesions Found by Capsule Endoscopy for Obscure Gastrointestinal Bleeding are in the Proximal Small Bowel
Scott D, Craig P.
- 74 Endoscopic Ultrasound Guided FNA of Solid Pancreatic Lesions: Performance and Outcomes in a Newly Established Service
Fischer L, Segarajasingam D, Ee H, Stewart C, Deboer W, Yusoff I.
- 75 Percutaneous Endoscopic Gastrostomy: An Eight-Year Prospective Follow up
Paramsothy S, Mollison L, Leong R.
- 76 Causes and Effects of Poor Bowel Preparation in Colonoscopy – A Retrospective Study
Grieve R, Morcom J, Andrews J.
- 77 Prospective Study of the Clinical Outcomes of a Tertiary Referral Coloscopy Service (TRCS)
Alexander S, Bourke J, Williams S, Bailey A, Pattullo V, Co J, Mishra A.
- 78 Implementation of an Evidenced Based Protocol for the Management of Bleeding Peptic Ulcer Disease
Bampton P, Sandford J, Young G.

- 79 Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) is a Safe Minimally Invasive Procedure for Biopsy of Pancreatic Tumor and Lymph Node (LN)
Co J, Kaffes A, Kwan V, Bailey A, Alexander S, Lee E, Patullo V, Mishra A, Williams S, Bourke M.
- 80 Repeat Gastroscopy after Initial Diagnosis of Benign Gastric Ulcer has a Low Yield of Detecting Cancer
Al-Sohaily S, Suttor V, Batey R, Leong R.
- 81 Occupational Related Injury in Endoscopists
Lee T, Valiozis I.
- 82 Double-Balloon Enteroscopy: The Royal Brisbane and Women's Hospital Experience
Philcox S, Appleyard M, Remedios M.
- 83 Negative Capsule Endoscopy Predicts A Positive Outcome And A Low Risk Of Further Intervention In Patients With Obscure Gastrointestinal Bleeding
Terkasher B, Feller R.
- 84 Deep Small Bowel Intubation During Double-Balloon Enteroscopy: is there a Learning Curve?
Prasad S, Kalade A, Desmond P1, Taylor A.
- 85 Connective Tissue Disorder – A New Subgroup of Boys with Slow Transit Constipation?
Chase J, Reilly D, Hutson J, Clarke M, Gibb S, Stillman B, Southwell B.
- 86 Age-Related Changes in Visceral Sensory Function: Symptom Response During a Standardised Nutrient Challenge Test
Gururatsakul M, Adam B, Liebrechts T, Lyngkaran G, Holloway R, Talley N, Holtmann G.
- 87 Interaction between Small Intestinal Motility and Absorption following Major Abdominal Surgery
Nguyen N, Bryant L, Fraser R, Burgstad C, Burnett J, Walsh J, Stanley B, Butler R, Holloway R.
- 88 Patient Tolerability and Compliance of Oesophageal Manometry and 24 Hour PH Study. A Patient Satisfaction Survey
Parker L, Woodward I, Foster N, Collins B, Siah C.
- 89 Pan-Colonic ISO-Contour MAPS of Propagating Pressure Wave Activity: Providing Patho-Physiological Insights into Constipation
Dinning P, Szczesniak M, Cook I.
- 90 Bioimpedance Phase Angle as a Marker of Improvement in Nutritional Status of Patients with Liver Cirrhosis
Plank L, Mathur S, Gane E, Gillanders L, McIlroy K McCall J.
- 91 Parenteral Nutrition (PN) in Adults with Fistulae at Royal Brisbane and Women's Hospital (RBWH)
Chapman-Kiddell C, Gleeson P, Gillen L, Radford-Smith G.
- 92 A Teaching DVD for Home Parenteral Nutrition Patients
Sanderson J, Gillanders L, McIlroy K, Parry B.
- 93 Evaluating the Success of a Medpass Program in a Clinical Setting
Drake A, Barker L.
- 94 Severe Zinc Deficiency During Total Parenteral Nutrition - It Still Exists
Jones L, Lamb S, Storey D.
- 95 Reversal Of IVN-Induced Cholestasis by use of Fish Oil –Based Fat Emulsion – A Case Report
Hill S, Bowden K, Allnutt A. Walmsley R.

- 96 Gestational parenteral nutrition support for a woman who has not eaten for 28 years
Ali A, Pascoe A, Murrell K.
- 97 Preventing Functional Decline In Elderly General Medical Patients, A New Role; The Nutrition Allied Health Assistant
Bramley A, Hughes M, Clough L.
- 98 The Influence of Neocate® in Paediatric Short Bowel Syndrome on PN Weaning
De Greef E, Mahler T, Janssen A, Cuypers H, Veereman-Wauters G.
- 99 Evidence Based Safe Pre Procedural Fasting For Children; Evaluation of Parent Information
Hall C.
- 100 Safety and Efficacy of Paediatric Gastroscopy by Adult-Trained Gastroenterologists for Foreign Body Ingestion
Fanning S, Bollipo S, Mitchell B, Middleton C, Wettenhall J, Rajendra S.
- 101 Current Practices of Australasian Hospitals Providing Micronutrients in Parenteral Nutrition
Spencer A, Hardy G.
- 102 Gastrointestinal Absorption Of Esterified Butyrate After Ingestion Of Acylated Starch By Volunteers
Clarke J, Bird T, Topping D, Royle P, Cobiac L.
- 103 Post-Operative Chylothorax in Children: An Evidence Based Management Algorithm
Panthongviriyakul C, Bines J.
- 104 Australasian Survey of the Current Role of Hospital Pharmacists in Nutrition Support
Poon A, Ogden S, Hardy G.
- 105 Costs of Malnutrition in the Development of Pressure Ulcers in Australian Hospitals
Banks M, Bauer J, Graves N, Ash S.
- 106 Faecal S100A12 is a Sensitive and Specific Test in Children with GI Symptoms Suggestive of Inflammatory Bowel Disease
Sidler M, Leach S, Day A.
- 107 Rare Tumour of the Oesophagus – A Case Report
Samarasam I, Chandran S, Kurian S, Mathew G.
- 108 The Seroprevalence of Helicobacter Pylorii in Jakarta: Samples from 5 Cities Area
Syam A, Fauzi A, Abdullah M, Simadibrata M, Makmun D, Manan C, Rani A, Daldiyono.
- 109 Oesophageal Cancer in Indigenous and Non-Indigenous Australians in Far North Queensland
V Ho, D Whiteman, J Ombiga, P Boyd.
- 110 **WITHDRAWN**
- 111 The Classic Watermelon Pattern of Gastric Antral Vascular Ectasia may be more Strongly Associated with Connective Tissue Diseases than the Diffuse Pattern
Prasad S, Desmond P, Taylor A.

LIVER:

- 112 The Role of Adiponectin and its Receptors in Hepatic Fibrogenesis
Ramezani-Moghadam M, Wang J, London R, Brymora J, George J.
- 113 Dysregulation of Normal Muscle and Liver Function may Contribute to Hepatic Steatosis in the MCD Nutritional Model of Steatohepatitis
London R, Van der Poorten D, Hurrell J, Joseph S, Ho V, Clouston A, George J.
- 114 Nuclear Receptor Ligands and their Role in Liver Injury in a Nutritional Model of Steatohepatitis
London R, George J, Hurrell J, Sessa J, Ho V, Coulter S, Brymora J, Clouston A, Liddle C, Hadengue A.
- 115 Human Discoidin Domain Receptor 1: Intrahepatic Forms and In Vitro Functions
Song Sunmi, Shackel N, Wang X-M, Ajami K, McCaughan G, Gorrell M.
- 116 Symptomatic Ophthalmologic Complications In Chronic Hepatitis C Patients Treated With Combination Interferon And Ribavirin: Experience In A West Australian Centre
Tan T, Kontorinis N, Tarquinio L, Edmunds S, Nazareth S, Mcinerney M, Connelly C, Cheng W.
- 117 Chronic Hepatitis B Infection in SSWAHS; Antenatal Screening Detects High Rates of Previously Unrecognised Cases
Holden, SL, Fraser, M, Glass, A, Kidson, B, Levy M.
- 118 National Standards for the Education and Accreditation of Community Practitioners to Prescribe HCV S100 Drugs
Crooks L, Conway D, Hill S, Pell C.
- 119 Evaluating the Hepatitis C Community Prescribing Pilot
Crooks L, Pell C, Hill S, Spina A.
- 120 ERCP In the Management of Biliary Complications of Orthotopic Liver Transplantation
AlGhamdi H, Kaffes A, Martin J.
- 121 Comparison of the Hepascore and Laine Serum Marker Models for the Prediction of Liver Fibrosis in Patients with Chronic Hepatitis C.
Venugopal K, Rossi E, Adams L, de Boer B, Jeffrey G, MacQuillan G.
- 122 Assessment of Carbohydrate-Deficient Transferrin and Y-Gutamyl Tanspeptidase Activity as Mrkers of Acohol Cnsumption in HCV Dsease.
Venugopal K, Rossi E, de Boer B, Adams L, Jeffrey G, MacQuillan G.
- 123 WITHDRAWN
- 124 Patient Information Available at the Point-of-Diagnosis: it Works for HIV – why not Viral Hepatitis?
Crooks L, Doyle L, Webb C.
- 125 Criteria for Analysis and Standardization of Morphological Types of Hepatic Veins - Anatomical Bases in Liver Imagistic Studies
Matusz P, Pusztai A, Zahoi D, Hordovan E, Hogeia B.
- 126 A New Upper Limit for Alanine Aminotransferase and Risk Factors for Raised Alt and Hepatitis C in Adolescents: a Study of 439 Male Adolescent Offenders on Community Orders.
Van der Poorten D, Kenny D, George J.
- 127 Energy Expenditure in Cirrhosis: Relationship to Disease Severity and Accuracy of Predictive Energy Equations in Progressive Liver Dysfunction
Ali A, Vivanti A, Abbott-Johnson W, Crawford D.

- 128 The Short-Term Costs of Managing Conditions Associated with Overweight and Obesity Among Australian Teenagers
Booth M, Dobbins T, Denney-Wilson E, Hardy L, Okely A, George J, Sullivan D, Cowell C.
- 129 Hepatic Steatosis Correlates with Central Obesity and Haemochromatosis but not Other Liver Diseases.
Williams E, Francis L, Whiteman D, Macdonald G A.
- 130 A Single Centre Experience of the use of Mycophenolate Mofetil for Autoimmune Hepatitis
Pattullo V, Napoli J, Jones B.
- 131 Transarterial Chemoembolisation using Drug Eluting Beads for Hepatocellular Carcinoma-Response and Side Effect Profile
Smith B, Tibballs J, Ferguson J, deBoer B, Jeffrey G, Adams L, Delriviere L, Mitchell A, Macquillan G.
- 132 Mycophenolate Mofetil Rescue Therapy in Autoimmune Hepatitis
De Cruz P, Angus P, Roberts S.
- 133 Effect of Liver Fibrosis on Management of Hepatitis C
Arachchi N, Mellor K, Watson K, Bell S, Desmond P.
- 134 Incidence and Impact of Neuro Psychiatric Side Effects on HCV Treatment: St Vincent's Hospital Experience
Arachchi N, Mellor K, Watson K, Bell S, Desmond P.
- 135 A Multivariate Analysis of Hepatitis C (HCV) Recurrence Post Transplantation Indicates that Early Peak Viral Load Levels are Associated with Liver Failure
Shackel N, Jamias J, Rahman W, Strasser S, Koorey D, McGuinness P, Guney S, McCaughan G W.
- 136 Occult Piggyback Syndrome Post Liver Transplantation and Response to Stenting of Right Hepatic Vein
De Silva M, Teo M, Chen J, Wigg A.
- 137 Sustained Virological Response (SVR) with Combination Pegylated Interferon/Ribavirin (PEG/RBV) in Chronic Hepatitis C Patients Failing to Respond to Standard Interferon Based Regimes
Studd C, Mollison L, Andrews G, Booth L, Miczkova S.
- 138 Neuropsychiatric Symptoms in Chronic Hepatitis C are Associated with Genotype 3, Steatosis and Fibrosis
Lang C, Dunne M, McGivern A, Macdonald G.
- 139 Fatigue Improves after Successful Antiviral Therapy for Hepatitis C
McDonald J, Bindley P, Gonsalvez C.
- 140 Long Lasting Side Effects of Pegylated Interferon and the Need of the Supporter as a Reporter
De Cruz P, Couper J, Gerraty R, Nicoll A, Watson K.
- 141 Vitamin D Deficiency is Prevalent in all Forms of Liver Disease
Rode A, Fourlanos S, Paizis G, Prichard P, Nicoll A.
- 142 Antiviral Efficacy of Entecavir in Previously Treatment Naive Patients with Chronic Hepatitis B
Nguyen T, Demediuk B, Shaw G, Chen R, Desmond P, Bell S.
- 143 Diurnal Sleep Disturbance in Hepatitis C Patients
Teoh W, Bindley P, McDonald J.
- 144 Ultra Rapid Virologic Response Predicts Sustained Virologic Response in HCV Infected Patients With Genotype 3 and High Viral Load: The GET-C Study
Pianko S, Sievert W, Gane E, Harley H, Bowden S, McCaw R, Palmer P, Perlman M, McClelland K, Law C.

- 145 Symptoms of HCV are worse with Psychosocial Distress Rather than Disease Severity
Teoh W, Bindley P, McDonald J.
- 146 Integrated Hepatitis C Treatment for Active Drug Users
Thompson A, Austin K, Kelsall J, Scholz R, Sasadeusz J, Walsh N.
- 147 The First Telehealth Service for the Management of Patients with Hepatitis C in Australia – an Innovative and Effective Model of Care in Patients in Remote Areas
Nazareth S, Kontorinis N, Hamilton A, Cheng W.
- 148 Adherence and Treatment Response of the HCV Shared Care Treatment Model in Remote Areas Compared to Tertiary Liver Clinics
Nazareth S, Kontorinis N, Tarquinio L, Jamil K, McInerney M, Connelly C, Flexman J, Cheng W.
- 149 Severe Psychiatric Complications Developing During Treatment of Chronic Hepatitis C
Dobson J, Kontorinis N, Nazareth S, Tarquinio L, Allet L, McInerney M, Connelly C, Cheng W.
- 150 Treatment of HIV/HCV Co-Infected Patients: A Challenging Population
Dobson J, Cheng W, Tarquinio L, Nazareth S, McInerney M, Connolly C, Mallal S, French M, Nolan D, Lucas M, Herrmann S, Kontorinis N.
- 151 The Prevalence of Insulin Resistance in HCV-Infected Patients
Dobson J, Cheng W, Tarquinio L, Nazareth S, McInerney M, Connelly C, Kontorinis N.
- 152 Adherence and Sustained Virological Response to HCV Treatment in Asians Compared to Caucasians in a Tertiary Centre
Dobson J, Kontorinis N, Tarquinio L, Nazareth S, Flexman J, McInerney M, Connolly C, Chen S-L, Foster N, Cheng W.
- 153 A Study into General Practitioners' Knowledge and Management of Viral Hepatitis
Guirgis M, Yan K, Bu Y, Zekry A.
- 154 Nurse Practitioner - Led Clinic Increases Access to Treatment and Optimises Compliance and Adherence for Patients with HCV
Nazareth S, Kontorinis N, Tarquinio L, Dobson J, Flexman J, Cheng W.
- 155 Phlebotomy is Associated with an Improvement in Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease and Increased Hepatic Iron Stores
Williams E, Dixon J, Powell L, Macdonald G.
- 156 The Prevalence and Phenotypic Characteristics of Western Australian Adolescents with Non-Alcoholic Fatty Liver Disease
Ayonrinde O, Adams L, Beilin L, Mori T, Shipman P, Sloan N, Oddy W, Olynyk J.
- 157 Cure Rates of Chronic Hepatitis C Following Treatment with Pegylated Interferon and Ribavirin: Report From a Single Centre Liver Clinic
Humphris J, Simring A, Ngu M, Lee A.
- 158 Preventive use of Probiotics in Chronic Liver Disease
Wong M, Gibson P, Dudley F, Chin-Dusting J.
- 159 Chronic Hepatitis B and E Antigen Status – Differences in Patient Characteristics and Management Patterns
Croagh C, Bell S, Thompson A, Arachchi N, Demediuk B, Shaw G, Chen R, Watson K, Desmond P.

- 160 Correlations Between on Treatment Seroconversion and Viral Suppression in HBEAG Positive Chronic Hepatitis B.
Croagh C, Bell S, Thompson A, Arachchi N, Demediuk B, Shaw G, Chen R, Watson K, Desmond P.
- 161 Effect of Type 2 Diabetes and Nash upon Outcomes in Hepatocellular Carcinoma
Howell J, Gibson R, Thompson B, Stella D, Pritchard P, Nicoll A.
- 162 Success of Non-Responders/Relapsers of Hepatitis C Infection Re-Treated with Pegylated IFN and Ribavirin: The Royal Adelaide Hospital Experience.
Tse E, Van Langenberg D, Coleman A, Harley H.
- 163 Diabetic Control Correlates with Abnormal LFTS in Fatty Liver Disease
Shelton, E, Khaw D, Colman P, Furlanas S, Nicoll A.
- 164 Paediatric Chronic Hepatitis B Infection in NSW, Australia
Nightingale S, O'Loughlin E, Stormon M.
- 165 Hepatitis C: Factors Affecting Disease Severity and Response to Treatment
Tan M, Chan C, Koh A, Hansen R, Jones B.
- 166 Non-Alcoholic Fatty Liver Disease in Bariatric Patients
Yan K, Guirgjs M, Bu Y, Loi K, Jorgensen J, Talbot M, Zekry A.
- 167 Prediction of Clinical Outcomes in Post-Transplant Recurrent Hepatitis C Using a Cluster of Differentiation (CD) Antibody Microarray
Rahman W, Huang P, Belov L, Jamias J, Prakaso E, Chrisp J, Koorey D, Strasser S, McCaughan G, Shackel N.
- 168 Outcome of Nucleos(T)IDE Analogue Therapy for Hepatitis B in a Clinical Setting: The Challenges of Viral Suppression
Ratnam D, Tabatabai S, Sievert W, Rusli F, Dev A, Knight V, Davey A, Pianko S.
- 169 Hepatitis C and Opioid Dependence Treatment Services in New South Wales
Digiusto E, Batey R, McPherson M, Ang J, Leist T.
- 170 Re-Infection with a New Genotype of Hepatitis C Virus (HCV) After Successful Antiviral Therapy.
Agarwal V, Booth L, Andrews G, Mollison L.
- 171 Glucose and Lipid Metabolism is Altered in Chronic Hepatitis (HBV) Infection Compared with HBV Seroclearance
Ryan M, Sung K, Wilson A, Reaven G.
- 172 Relationships Between Adiposity, Insulin Resistance and Nonalcoholic Liver Disease in a Large Group of Nondiabetic Korean Adults
Sung K, Ryan M, Kim B, Cho Y, Kim B, Reaven G.
- 173 Audit of Eosinophilic Esophagitis (EE) in Children Post Liver Transplantation.
Noble C, Ee L, Withers G, Cleghorn G, Lewindon P.

Invited Faculty

Leon Adams

Fremantle Hospital
FREMANTLE WA

Katrina Allen

Murdoch Children's Research Institute
PARKVILLE VIC

Robert Anderson

Department of Gastroenterology
Royal Melbourne Hospital
PARKVILLE VIC

Jane Andrews

Jason Antenucci

Centre for Water Research
University of Western Australia
PERTH WA

Mark Appleyard

Endoscopy Unit
Royal Brisbane Hospital
HERSTON QLD

Merrilyn Banks

Royal Brisbane & Women's Hospital
HERSTON QLD

Robert Batey

Department of Gastroenterology
John Hunter Hospital
NEWCASTLE NSW

Cameron Bell

Department of Gastroenterology
Royal North Shore Hospital
ST LEONARDS NSW

Prithi Bhathal

Department of Pathology
University of Melbourne
MELBOURNE VIC

Julie Bines

Department of Gastroenterology &
Nutrition
Royal Children's Hospital
PARKVILLE VIC

Ashley Blackshaw

Michael Bourke

Endoscopy Unit
Westmead hospital
WESTMEAD NSW

Gregor Brown

Department of Colorectal Medicine &
Genetics
Royal Melbourne Hospital
PARKVILLE VIC

Stephanie Buckton

Nambour Community Health Centre
NAMBOUR QLD

Donald Cameron

Royal Children's Hospital
PARKVILLE VIC

Andre Chong

Gastroenterology Department
Fremantle Hospital
FREMANTLE WA

William Connell

Department of Gastroenterology
St Vincent's Hospital
FITZROY VIC

Philip Craig

St George Private Medical Centre
KOGARAH NSW

Darrell Crawford

Department of Gastroenterology
& Hepatology
Princess Alexandra Hospital
WOOLLOONGABBA QLD

Suzie Daniells

Prince of Wales Hospital
RANDWICK NSW

Andrew Davies

Intensive Care Unit
The Alfred Hospital
PRAHRAN VIC

Andrew Day

Gastroenterology Department
Sydney Children's Hospital
RANDWICK NSW

Paul Desmond

St Vincent's Hospital
FITZROY VIC

David Devonshire

Monash Medical Centre
CLAYTON VIC

Greg Dore

National Centre in HIV Epidemiology &
Clinical Research
SYDNEY NSW

Simon Edmunds

Consultant Gastroenterologist
Royal Perth Hospital
PERTH WA

Paul Edwards

Private Practice
WOOLWICH NSW

Elizabeth Eyres

GLENNING VALLEY NSW

Geoffrey Farrell

Department of Gastroenterology
The Canberra Hospital
WODEN ACT

James Ferguson

Linda Fletcher

Princess Alexandra Hospital
WOOLLOONGABBA QLD

Timothy Florin

Department of Medicine
Mater Adult Hospital
SOUTH BRISBANE QLD

[David Forbes](#)
Department of Paediatrics
Princess Margaret Hospital for Children
PERTH WA

[Geoffrey Forbes](#)
Department of Gastroenterology
Royal Perth Hospital
PERTH WA

[Vincent Fragomelli](#)
SYDNEY NSW

[Peter Gibson](#)
Department of Gastroenterology
Box Hill Hospital
BOX HILL VIC

[Lyn Gillanders](#)
Auckland Hospital
AUCKLAND NEW ZEALAND

[Paul Haber](#)
Drug and Alcohol Services
Royal Prince Alfred Hospital
CAMPERDOWN NSW

[Sebastian Haag](#)

[Melissa Haines](#)
Department of Gastroenterology
Box Hill Hospital
BOX HILL VIC

[Richard Hallinan](#)
The Byrne Surgery
REDFERN NSW

[Lois Hamlin](#)
Faculty of Nursing, Midwifery & Health
University of Technology
LINDFIELD NSW

[Melissa Hands](#)

[Robyn Harvey](#)
GLADESVILLE NSW

[Ralf Heine](#)
Department of Gastroenterology
Royal Children's Hospital
PARKVILLE VIC

[Lyn Hellier](#)
Acute Pain Service
Sir Charles Gairdner Hospital
NEDLANDS WA

[Matthew Hipsey](#)
Centre for Water Research
University of Western Australia
PERTH WA

[Rupert Hodder](#)
Department of General Medicine
Sir Charles Gairdner Hospital
NEDLANDS WA

[Linda Hodge](#)
Dietitian
SYDNEY NSW

[Richard Holloway](#)
Department of Gastrointestinal
Medicine
Royal Adelaide Hospital
ADELAIDE SA

[Gerald Holtmann](#)
Department of Gastroenterology
Royal Adelaide Hospital
ADELAIDE SA

[Graham Hool](#)
Royal Perth Hospital
PERTH WA

[Andrew Horobin](#)
LEEDERVILLE WA

[Mariko Howlett](#)
Princess Alexandra Hospital
WOOLLOONGABBA QLD

[John Iser](#)
Private Practice
BALWYN NORTH VIC

[Gary Jeffrey](#)
Department of Medicine
Fremantle Hospital
FREMANTLE WA

[Penny Johnston](#)
In Vivo Medical Pty Ltd
ST LEONARDS NSW

[Dianne Jones](#)
Logan Hospital
MEADOWBROOK QLD

[Paul Kerlin](#)
Wesley Medical Centre
AUCHENFLOWER QLD

[Susannah King](#)
Faculty of Medicine, Nursing and
Health Sciences
Monash University
CLAYTON VIC

[Ross Knight](#)
Private Practice
GEELONG VIC

[Matthew Law](#)
National Centre in HIV Epidemiology
and Clinical Research
University of New South Wales
SYDNEY NSW

[Peta Leach](#)
Department of Gastroenterology
Flinders Medical Centre
BEDFORD PARK SA

[Karin Leder](#)
Infectious Disease Epidemiology Unit
Monash University
CLAYTON VIC

Rupert Leong
Concord Hospital
CONCORD NSW

Miriam Levy
Department of Gastroenterology
Liverpool Hospital
LIVERPOOL NSW

Sharon Lewin
Director of Infectious Diseases
The Alfred Hospital
PRAHRAN VIC

Stephen Locarnini
Victorian Infectious Diseases
Laboratory
NORTH MELBOURNE VIC

Graeme Macdonald
Department of
Gastroenterology & Hepatology
Princess Alexandra Hospital
WOOLLOONGABBA QLD

Darryl Mackender
Private Practice
ORANGE NSW

Finlay Macrae
Royal Melbourne Hospital
PARKVILLE VIC

Gregory Makin
Colorectal Cancer Unit
St John of God Hospital
SUBIACO WA

Barry Marshall
Nobel Laureate
PERTH WA

Sue Mason
Department of Gastroenterology
& Hepatology
Royal Brisbane Hospital
HERSTON QLD

Rebecca McCann
National Coordinator Infection
Control Services
St John of God Hospital
MURDOCH WA

Geoffrey McCaughan
AW Morrow Gastroenterology &
Liver Centre
Royal Prince Alfred Hospital
CAMPERDOWN NSW

Carol McCrae
Box Hill Hospital
BOX HILL VIC

Mark McCullen
Department of
Gastroenterology & Hepatology
Royal Brisbane Hospital
HERSTON QLD

Kerry McIlroy
Nutrition Services
Auckland Hospital
AUCKLAND NEW ZEALAND

Rene Michael
School of Nursing and Midwifery
Curtin University of Technology
PERTH WA

Antonina Mikocka-Walus
Division of General Practice
University of Adelaide
ADELAIDE SA

Sue Morey
Department of Respiratory Medicine
Sir Charles Gairdner Hospital
NEDLANDS WA

Amanda Nicoll
Department of Gastroenterology
Royal Melbourne Hospital
PARKVILLE VIC

Ian Norton
Department of Gastroenterology
Royal North Shore Hospital
ST LEONARDS NSW

Ibolya Nyulasi
Nutrition Department
The Alfred Hospital
PRAHRAN VIC

John Olynyk
Department of Medicine
Fremantle Hospital
FREMANTLE WA

Donald Ormonde
Private Practice
SUBIACO WA

Marissa Otuszewski
Director
Bowel Cancer Screening Section
Department of Health & Ageing
CANBERRA ACT

Sebastien Ourselin
CSIRO e-Health Research Centre
BRISBANE QLD

Joanne Parnell
Guild Insurance
WEST PERTH WA

Donald Payne
Princess Margaret Hospital for Children
PERTH WA

Prue Pereira-Fantini
Murdoch children's Research Institute
PARKVILLE VIC

Stephen Pianko
Monash Medical Centre
CLAYTON VIC

Angela Poon
Westmead Hospital
WESTMEAD NSW

Peter Prichard
Epworth Medical Centre
RICHMOND VIC

Lynn Rapley
North Gosford Private Hospital
NORTH GOSFORD NSW

[Lai Wan Reid](#)

Eastern Clinical Research Unit
BOX HILL VIC

[Jeanette Robertson](#)

Princess Margaret Hospital for Children
PERTH WA

[Dee Roche](#)

AIM-UWA Business School Alliance
PERTH WA

[Elizabeth Rogers](#)

Department of Nutrition & Dietetics
Royal Children's Hospital
PARKVILLE VIC

[Douglas Routley](#)

Private Practice
NEW LAMBTON NSW

[Rebecca Ryan](#)

Princess Alexandra Hospital
WOOLLOONGABBA QLD

[Mark Schoeman](#)

Department of Gastroenterology
Royal Adelaide Hospital
ADELAIDE SA

[Warwick Selby](#)

Royal Prince Alfred Hospital
CAMPERDOWN NSW

[Nicholas Shackel](#)

Centenary Institute of Cancer Medicine
and Cell Biology
CAMPERDOWN NSW

[Helen Shalley](#)

Royal Children's Hospital
PARKVILLE VIC

[Sue Shepherd](#)

Department of Gastroenterology
Box Hill Hospital
BOX HILL VIC

[Chiang Siah](#)

Consultant Gastroenterologist
Royal Perth Hospital
PERTH WA

[Bridget Southwell](#)

Department of Gastroenterology
Royal children's Hospital
PARKVILLE VIC

[Miles Sparrow](#)

Department of Gastroenterology
Box Hill Hospital
BOX HILL VIC

[Nicole Staples](#)

Department of Haematology
Royal Perth Hospital
PERTH WA

[Simone Strasser](#)

AW Morrow Liver &
Gastroenterology Centre
Royal Prince Alfred Hospital
CAMPERDOWN NSW

[William Tam](#)

Department of Gastroenterology
Royal Adelaide Hospital
ADELAIDE SA

[Andrew Taylor](#)

Department of Gastroenterology
St Vincent's Hospital
FITZROY VIC

[Dana Thacker](#)

Gastrointestinal Investigation Unit &
Ambulatory Services
Royal Adelaide Hospital
ADELAIDE SA

[Alexander Thompson](#)

Department of Gastroenterology
St Vincent's Hospital
FITZROY VIC

[Leanne Totten](#)

Fremantle Hospital
FREMANTLE WA

[Russell Walmsley](#)

North Shore Hospital
AUCKLAND NEW ZEALAND

[Justin Waring](#)

Respiratory Medicine
Royal Perth Hospital
PERTH WA

[Annette Webb](#)

Dept Of Gastroenterology &
Clinical Nutrition
Royal Children's Hospital
PARKVILLE VIC

[David Williams](#)

Endoscopy Unit
St Vincent's Hospital
DARLINGHURST NSW

[Paul Woods](#)

Hollywood Private Hospital
PERTH WA

[Simon Worrall](#)

School of Molecular &
Microbial Sciences
The University of Queensland
BRISBANE QLD

[Jan Wright](#)

Royal Perth Hospital
PERTH WA

[Graeme Young](#)

Department of Gastroenterology
Flinders Medical Centre
BEDFORD PARK SA

[Nazy Zarshenas](#)

Nutrition & Dietetics Department
St George Hospital
KOGARAH NSW

[Amany Zekry](#)

St George Hospital
The University of New South Wales
SYDNEY NSW



Company Profiles Sponsors 2007



ASTRAZENECA

AstraZeneca is one of the world's largest and most successful pharmaceutical companies. With more than 1,000 employees, the company invests hundreds of millions of dollars in local research and manufacturing.

AstraZeneca excels in providing healthcare solutions across seven major therapeutic areas including cardiovascular, neuroscience, gastrointestinal, infection, oncology, pain control and anaesthesia and respiratory medicines.

At any given time, AstraZeneca is participating in more than 40 clinical trials across 200 centres around the country. In 2006, \$20 million was invested in Australian clinical research projects.

Globally we spend more than \$15 million each working day on R&D with more than 12,000 researchers dedicated to the discovery and development of innovative new medicines that meet the needs of patients worldwide.

With a global business comes a global responsibility and, along with our commitment to competitiveness and performance, we will continue to be led by our core values to achieve sustainable success.

AstraZeneca believes that it has a global responsibility to its customers and the communities they live in.

Through financial support and representation, AstraZeneca recognises the work and commitment of patient care and advocacy groups. These important partnerships are central to our commitment to improve the quality of people's lives.

AstraZeneca has a strong history of supporting the local community and last year donated almost \$500,000 to 29 charities and foundations including the National Heart Foundation and the National Breast Cancer Foundation. In 2005, AstraZeneca announced its AUD \$75,000 partnership with Redkite, a children's cancer charity.

Every day, more than 1.5 million Australians benefit from our medicines.



NYCOMED

Nycomed, as a pioneering pharmaceutical organisation in Australia and New Zealand, is committed to an investment in the countries' healthcare systems.

With our innovative products and support activities including Research we add value to patients' lives. We strive for a leadership position in the fields of our expertise, by engaging in constant value innovation and delivering the highest standard in customer service.

Our performance and long term success provides the foundation for our overall contribution to the Australian and New Zealand societies. As a research-based company with global operations, Nycomed is contributing to sustainable improvements in the quality of patients' lives by supplying innovative and established therapies.

The company researches, develops and produces a wide range of pharmaceuticals.

The main emphasis of our business is prescription drugs from our own research pipeline destined to treat gastrointestinal and respiratory diseases.



JANSSEN-CILAG

Janssen-Cilag Australia is a member of the Johnson & Johnson Family of Companies, the global leader in healthcare and in the production of pharmaceuticals, biotechnology, medical devices and consumer health related products.

Janssen-Cilag Australia is a leading research-based pharmaceutical company, dedicated to improving the health and well being of all Australians. Our research accomplishments have opened up new areas of knowledge. In past years, over 75 drugs have been developed from the molecules created by Janssen-Cilag. This rate of discovery makes Janssen-Cilag one of the most innovative pharmaceutical companies in the world.

The organisation's commitment to world-class research has created hundreds of job opportunities for highly trained Australians. Key research areas for Janssen-Cilag are the central nervous system, oncology, mental disorders, the gastro-intestinal system and renal failure.

Research into the health challenges facing Australians has resulted in a number of critical medicines being developed and made available to the Australian public. These include Risperdal, used for the treatment of schizophrenia, Reminyl a medicine designed to combat the debilitating symptoms of Alzheimer's Disease, Topamax used in the control of epilepsy, Pariet a treatment for gastro-oesophageal reflux disease, Eprex vital for combating anaemia in renal failure and oncology, Prograf which is an immunosuppressant used in organ transplantation and Durogesic a transdermal fentanyl patch delivery device for relief from chronic and severe pain.

Janssen-Cilag has been a committed corporate sponsor of the Gastroenterology Society of Australia (GESA) since 2006 contributing to the four key areas of the society: research (including the Janssen-Cilag GESA research fellowship), education, scientific meetings (such as AGW) and communication.

Janssen-Cilag Australia takes the greatest possible care with the well being of our patients, our employees, our fellow citizens and our environment.



ABBOTT AUSTRALASIA

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals and devices. The company employs 65,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com

Abbott recently announced that the Therapeutic Goods Administration (TGA), has approved HUMIRA® (adalimumab) for the treatment of adults with moderate to severe Crohn's disease. HUMIRA is a self-administered biologic for the treatment of Crohn's disease.



BRISTOL-MYERS SQUIBB

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Operating in Australia since 1930, Bristol-Myers Squibb is dedicated to discovering and developing innovative, cost-effective medicines addressing significant medical needs in key disease areas. These include: cancer, atherosclerosis/thrombosis, diabetes, obesity, psychiatric disorders, Alzheimer's disease, hepatitis, HIV/AIDS and rheumatoid arthritis.

While scientists have developed some effective therapies in recent years for hepatitis B and C, significant unmet medical needs still exist as a result of problems related to potency, resistance, and tolerability. Recognising the important unmet medical needs, Bristol-Myers Squibb is working to provide new treatments for both forms of this very widespread, highly infectious disease. In 2006, the company launched Baraclude® (entecavir) – a new treatment for hepatitis B - in Australia.



GILEAD SCIENCES

Gilead's mission is to advance patient care by developing ground-breaking therapeutics to treat life-threatening infectious diseases. We apply the best of biopharmaceutical science to create innovative medicines that bring new hope in the battles against HIV/AIDS (Truvada, Emtriva, Viread), chronic hepatitis B (Hepsera), and serious bacterial and systemic fungal infections (AmBisome).

In just 20 years, Gilead has become one of the largest biopharmaceutical companies in the world, with a rapidly expanding product portfolio, growing pipeline of investigational drugs, more than 2,700 employees and operations on three continents. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. The Australian and New Zealand head office is located in East Melbourne, Victoria.

Scientific breakthrough is almost always the product of collaboration and Gilead places high value on partnering with companies and organizations whose strengths complement and augment our own. Over the past two decades, we have forged many long-term collaborations with leading academic institutions and biotechnology and pharmaceutical companies to develop innovative new therapeutics and advance the care of patients confronting life-threatening diseases.

Gilead has an active research and development program to identify new and improved compounds for the treatment of HIV/AIDS, chronic hepatitis, respiratory and cardiopulmonary conditions, and other diseases that represent significant unmet medical needs. In 2006 alone, Gilead invested nearly \$380 million in research and development activities.

We look forward to seeing you at the Gilead Sciences booth at AGW.



OLYMPUS AUSTRALIA

Olympus has always concentrated our energies on areas where we can excel, not simply compete. Our greatest strength has always been our leadership in OPTO-digital Technologies. Consequently, this strength has earned Olympus undisputed leadership and a 75% share of the global endoscope market.

Olympus is proud of our High Definition 180 series endoscopes, featuring NBI, wide field of view and picture definition unsurpassed. These scopes offer the high performance and technology breakthroughs you demand from Olympus.

Olympus' EXERA II offers one High Definition imaging platform for the entire hospital, as it is compatible with approximately 200 endoscopic videoscopes and surgical high definition camera heads. We have bridged the needs of cost conscious management with the superb picture quality required by surgeons and practicality required by nursing staff.

Olympus has now completed the imaging chain through an integrated image capture and reporting system that allows seamless image capture, reporting and quality assurance tools required for running a modern day practice. Endobase connects directly to the Olympus Imaging equipment providing two-way communication between the devices.

Olympus continues to upgrade its lineup of EndoTherapy devices and provide total solutions to medical practitioners. The revolutionary V-System combines state-of-the-art endoscopes with high performance innovative EndoTherapy devices. This simplified system offers the Endoscopist the option to manipulate the device exchange on their own and is ideal for off-hours procedures. As with endoscopes, the development of EndoTherapy devices is realised only in tandem with the development of therapy techniques for doctors.

We look forward to seeing you at AGW 2008 - Booth #20



ORPHAN AUSTRALIA

With our continued commitment to Gastroenterology and continuing education, Orphan Australia is once again delighted to be a Major Sponsor of Australian Gastroenterology Week being held in Perth in 2007.

Based in Melbourne, Orphan Australia began operations in 1995 as an Australian owned pharmaceutical company dedicated to providing novel, highly specialized products to treat serious or life-threatening conditions where treatment choice is limited or inadequate.

Throughout the company's history, it's been our mission to deliver high quality pharmaceutical products to Australian Gastroenterologists and their patients. Over the years we have worked in consultation with GESA to be able to provide more therapeutic options for clinicians to improve patient outcomes. As a result Orphan Australia was the first company to introduce mesalazine enemas and granules for the treatment of ulcerative colitis, and we made 500 mg tablets available making it much easier for patients to comply with long term therapy. With your continuing support, it strengthens our involvement in this therapeutic area and we look forward to further product opportunities to respond to the needs of your patients well into the future.

As part of a successful and dynamic organisation, Orphan Australia strives for professionalism in everything we undertake, by recognising and embracing core values such as integrity, quality, customer focus, partnership and respect. These things drive us towards our vision of changing patients' lives for the better.

We invite you to visit us during AGW to find out more about our mission and the latest information about our products. Alternatively you can visit our website at www.orphan.com.au.



PHARMATEL FRESENIUS KABI

Pharmatel Fresenius Kabi is committed to delivering an exceptional level of service to our customers and an expanding range of products to Australian patients.

In a merger unique to the Australian market PFK brings together Pharmatel™s gastrointestinal expertise, local aseptic compounding & streamlined distribution network along with the internationally recognized infusion and nutrition expertise of Fresenius Kabi, offering:

Compounding –

With two expert compounding sites in Sydney and Melbourne PFK is able to develop logistical solutions to supply sterile infusion therapies.

Nutrition Therapy –

With well established products like Intralipid (triglycerides), Glamin (amino acids) and Vamin (amino acids), adding new solutions like Kabiven (TGA registered three chamber bag, multiple actives) PFK develops a matching range of nutrition solutions for the Australian market based on the international portfolio of Fresenius Kabi in enteral and parenteral nutrition

Gastroenterology –

With a consistent range of bowel cleansing products such as Picoprep (sodium picosulfate) and Glycoprep (magrolog 3350) PFK is able to pack specific sets matching the individual needs of the physician. New products such as Colazide® (balsalazide sodium) for the treatment of mild to moderate Ulcerative Colitis, PFK increases the options of Australian Gastroenterologists

Fluid Therapy –

PFK is offering a range of standard IV solutions and other iv solutions for anesthesia.

The aim of PFK is to improve patients quality of life and establish a new benchmark when it comes to servicing the needs of the Australian market, by developing customized solutions, matching the customer needs.




ROCHE PRODUCTS

Roche Products Pty Limited (Australia) is part of the International F. Hoffmann-La Roche Group worldwide that was founded in 1896 in Basel, Switzerland. Roche has grown from a small drug laboratory into one of the world's leading research-based Healthcare companies and is known for many innovative contributions to medicine. Arranged in two operative divisions, Pharmaceuticals and Diagnostics, our global mission today and tomorrow is to create exceptional added value in healthcare. Roche is a world leader in in-vitro diagnostics and medicines in the field of virology and are active in other major therapeutic areas such as oncology and autoimmune diseases.

Since its launch, PEGASYS® (peginterferon alfa-2a) has helped make a difference to the lives of many people living with hepatitis B and C. The benefits of PEGASYS® are derived from its large 40 kilodalton (KD) branched-chain polyethylene glycol (PEG) construction, which allows for sustained drug levels over the course of a full week. PEGASYS® is the only pegylated interferon available as a ready-to-administer solution. Each weekly subcutaneous injection contains 180 mcg of pegylated interferon alfa-2a (40KD), which is the approved dose for all patients, regardless of body weight. PEGASYS® is also the only pegylated interferon registered in Australia for the treatment of both hepatitis B and C.

As a leader in hepatitis, Roche's dedication extends beyond providing PEGASYS®. In Australia, Roche also offers a range of patient support materials, education programs and is committed to clinical research to optimise patient treatment with PEGASYS®.

 Schering-Plough Pty Limited **SCHERING-PLOUGH**

At the New Schering-Plough, we aspire to earn the trust of doctors, patients and customers by providing a steady flow of innovative, science-based medicines and services that improve the health and well-being of people around the world.

To achieve these goals and grow our company, we are working to earn the trust of all stakeholders. We understand that earning trust demands hard work, sharp execution, integrity and transparency


Our customers and patients are our most important constituents. Our vision for the New Schering-Plough clearly sets forth what we will do as a global team, what makes us special as a company and what will give us a competitive advantage

To become the best, we are getting back to basics and reinventing our company by driving positive change. We are focused on becoming the best in three key strategic areas: people, products and processes.

Schering-Plough offers medicines in the following areas: allergy & respiratory, arthritis and immunology, cancer therapies, cholesterol lowering, dermatological, gastroenterological, hepatitis C, hypertension, infectious diseases, cough, cold and flu.

Future Dates For Australian Gastroenterology Week

- 2008 Brisbane 22 – 25 October
- 2009 Sydney 19 – 24 October
- 2010 Melbourne 19 – 23 October



Gastroenterological
Society of Australia

145 Macquarie Street
SYDNEY NSW 2000
AUSTRALIA

Ph 61 2 9256 5454

Fax 61 2 9241 4586

Email gesa@gesa.org.au